{ "schemaVersion": "deck-intelligence.v1", "id": "019de075-f745-744d-a2c3-62fcecd316e9", "slug": "352ee416e6a97a9b39e1309fafdab0f3", "title": "Genelux | Investor Presentation Deck | 38 slides", "subtitle": "Genelux · 2023-10", "author": "Genelux", "date": "2023-10-01 00:00:00", "pageCount": 38, "kind": "pitchdeck", "orientation": "landscape", "aspectRatio": 1.7777778, "document": { "id": "019de075-f745-744d-a2c3-62fcecd316e9", "slug": "352ee416e6a97a9b39e1309fafdab0f3", "title": "Genelux | Investor Presentation Deck | 38 slides", "rawTitle": "Genelux | Investor Presentation Deck | 38 slides", "authorId": "genelux", "authorName": "Genelux", "authorDisplay": "Genelux", "kind": { "slug": "pitchdeck", "label": "Pitch deck" }, "sourceType": { "slug": "investor_relations", "label": "Investor relations" }, "fileName": "2023-10__genelux__investor-pres__352ee416.pdf", "sourceUrl": "https://www.slidebook.io/company/genelux/presentation/352ee416e6a97a9b39e1309fafdab0f3/", "sourceDate": "2023-10-15 00:00:00", "presentationDate": "2023-10-01 00:00:00", "ingestedAt": "2026-04-30 22:15:20.746402+00", "status": "ready", "pageCount": 38, "orientation": "landscape", "aspectRatio": 1.7777778, "targetCompany": null, "targetTicker": null, "metadata": { "corpus": "slidebook", "industry": "biotechnology", "local_root": "/Users/miguelsuredasuau/Desktop/lalalalla/_scrape/slidebook/decks/2023-10__genelux__investor-pres__352ee416", "image_width": 1920, "image_format": "jpg", "deck_type_raw": "Investor Presentation Deck", "deck_type_slug": null, "source_url_pattern": "https://www.slidebook.io/company/{company_slug}/presentation/{deck_id}/" } }, "coverage": { "pageCount": 38, "pagesIndexed": 38, "pagesWithImages": 38, "pagesWithMetadata": 38, "imageCoveragePct": 100, "metadataCoveragePct": 100, "componentCount": 201, "chartCount": 17, "metricSlides": 0, "toolMatches": 11, "documentToolMatches": 0, "frameworkMatches": 13, "arcMatches": 1, "beatMatches": 3, "loopMatches": 2, "patternMatches": 0, "storymakersMatch": false, "scoreAvailable": false, "reviewAvailable": false, "activistThesisAvailable": false, "pitchdeckMetadataAvailable": false, "pitchdeckProfileAvailable": false }, "blocks": [], "matches": { "arcs": [ { "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "matchId": "c6868580-ab1d-4db0-aaa6-d004c6bcc7ce", "evidence": "The deck follows a clear problem-agitate-solution structure, highlighting the limitations of current treatments, the complications of resistance and refractoriness, and the potential solution offered by Olvi-Vec.", "isPrimary": true, "confidence": 0.8, "extraction": { "at": "2026-07-16 22:38:33.75505+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "beats": [ { "to": 3, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 1, "name": "Problem (Identify pain)", "beatId": "e444b487-fcb2-4bdd-9b87-8dd886121483", "matchId": "c6868580-ab1d-4db0-aaa6-d004c6bcc7ce", "beatType": { "name": "Problem (Identify pain)", "slug": "problem-agitate-solution-problem-identify-pain", "status": "active", "canonId": "019dd9b8-0e78-74bb-b8f6-54348367a131", "version": 1, "description": null }, "evidence": "The initial slides introduce the problem and highlight the limitations of current oncolytic immunotherapies.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 9, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 4, "name": "Agitate (Make it worse)", "beatId": "fdbee508-b41b-482b-8db8-5d1f0a14e7b6", "matchId": "c6868580-ab1d-4db0-aaa6-d004c6bcc7ce", "beatType": { "name": "Agitate (Make it worse)", "slug": "problem-agitate-solution-agitate-make-it-worse", "status": "active", "canonId": "019dd9b8-0f5a-71dd-bae7-8fadb0d09456", "version": 1, "description": null }, "evidence": "Slides 4-9 emphasize the complications and challenges of current treatments, including resistance and refractoriness.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Development", "slug": "development", "status": "active", "canonId": "019dd9b8-0332-7008-b3aa-11b0840a57b1", "version": 1, "description": "The middle stretch in arcs that have one. Often where length problems creep in." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 38, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 10, "name": "Solution (Provide relief)", "beatId": "523d1cf4-1cd0-4572-8561-e435ff7a2275", "matchId": "c6868580-ab1d-4db0-aaa6-d004c6bcc7ce", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 10-38 present Olvi-Vec as a solution, detailing its competitive advantages, clinical results, and market potential.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 9, "from": 4, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null, "categoryName": "Urgency", "categorySlug": "urgency" }, "matchId": "38515402-0f9a-4e9b-81f7-00348eb645d5", "evidence": "The deck highlights the limitations and challenges of current treatments, implicitly raising the question of what if we don't innovate.", "position": 0, "objective": "What if we don't adopt a new approach to oncolytic immunotherapy?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:38:33.915904+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 26, "from": 24, "loop": { "name": "53_jobs_to_be_done", "slug": "53-jobs-to-be-done", "status": "active", "bestFor": "Product innovation, market entry, competitive positioning", "canonId": "019dd956-7b6c-7594-b5b3-eecbe0ab48e8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying", "familyLabel": null, "categoryName": "Consulting Framework", "categorySlug": "consulting-framework" }, "matchId": "392920d4-0517-46aa-a9c2-4fb0dd0c15fd", "evidence": "The deck discusses the market opportunity and commercial potential of Olvi-Vec, highlighting its potential to address unmet needs.", "position": 1, "objective": "How can Olvi-Vec address the needs of patients and healthcare systems?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:38:33.951008+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "tools": [ { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "cd8bb61a-bff7-4104-8cd8-c051b50b66c8", "evidence": "Validating Strategic Partnerships. Newsoara Biopharma (Greater China rights) initiated a Phase 1b/2 clinical trial with Olvi-Vec in small-cell lung cancer and ELIAS Animal Health (global rights) is preparing", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:33:36.150999+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "597ce2da-bc5d-4aa2-9957-2231e7cbb8a0", "evidence": "Pipeline table with columns: Olvi-Vec, Human Health, Design, Preclinical, Phase 1, Phase 2, Phase 3, Collaborators", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:33:32.323187+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "4d0b6645-d797-4a21-a80f-3702d1bd3a49", "evidence": "table/data: Data Presentations: 1. 2020 Digital Annual Meeting of International Gynecologic Cancer Society (Oral Plenary Session); 2. JAMA Oncology (Selected for Journal podcast series interview)", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:33:32.606235+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "db8e05a9-e4aa-4ae5-ac3e-669b215c078b", "evidence": "table/data: Overall Response Rate (ORR) & Progression-Free Survival (PFS)*", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:33:32.678177+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Audience Definition", "slug": "audience-definition", "status": "active", "bestFor": null, "canonId": "019dd956-7f2a-775d-aeee-ff099bcb7756", "version": 1, "bodyDocId": null, "description": "Six key questions: Who are they? What do they know? What do they believe? What do they care about? What do they fear? What decisions can they make?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "8a3c282d-8ac3-4e52-a6d1-ef4c0c5be02c", "evidence": "Olvi-Vec addresses a broad and underserved pool of patients", "pageRefs": null, "priority": "Core", "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:33:39.483357+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 17, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Problem Statement Canvas", "slug": "problem-statement-canvas", "status": "active", "bestFor": null, "canonId": "019dd956-839d-744b-ad11-9bf3e3642a18", "version": 1, "bodyDocId": null, "description": "Structured definition of the problem: What? Who? Where? When? Scale?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "fe0ebe8f-6ecf-4c2a-9bd1-8ee92844061d", "evidence": "Olvi-Vec trial inclusion criteria allows patients regardless of (i) tumor biomarkers, (ii) platinum refractory tumors, or (iii) number of prior lines of treatment", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.6, "extraction": { "at": "2026-07-17 00:33:39.521344+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 17, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "2x2 matrix", "slug": "matrix-2x2", "status": "active", "bestFor": null, "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8", "version": 1, "bodyDocId": null, "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "adb3a46b-052b-4ccd-8d22-f7ccf893e231", "evidence": "Experimental Arm: Olvi-Vec + Platinum-doublet + Bevacizumab. Active Comparator Arm: Platinum-doublet + Bevacizumab", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 00:33:39.597741+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 18, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Chart Selection Guide", "slug": "chart-selection-guide", "status": "active", "bestFor": null, "canonId": "019dd956-b1a0-700b-ba17-0e16c4d5bcae", "version": 1, "bodyDocId": null, "description": "Choosing the right chart type for your data and message", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "31baa5e5-0a3d-4e89-8302-286dbde027c8", "evidence": "Kaplan-Meier survival curves and dose escalation plots", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:33:39.67477+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 19, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Data Story Arc", "slug": "data-story-arc", "status": "active", "bestFor": null, "canonId": "019dd956-9c30-728e-b974-d3fb123dcf5a", "version": 1, "bodyDocId": null, "description": "Context → Conflict → Insight → Implication structure for data narratives", "familyLabel": null, "categoryName": "Loop", "categorySlug": "loop" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "47d87a43-7bea-4f96-8892-82f54357e873", "evidence": "Key Trial Takeaways: Anti-tumor effect of IV Immunochemotherapy; High and Condensed Dosing; Well tolerated; Monotherapy; Combination therapy", "pageRefs": null, "priority": "Core", "whenToUse": null, "confidence": 0.6, "extraction": { "at": "2026-07-17 00:33:39.749834+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 20, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Authority citation", "slug": "authority-citation", "status": "active", "bestFor": null, "canonId": "019dd9e1-49ae-7557-89ad-3fca70469b45", "version": 1, "bodyDocId": null, "description": "Quoting an authority figure, study, or precedent to lend weight.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "7054fa26-8532-4cef-bb5a-bed41ee1b307", "evidence": "Benny Li, PhD, Founder and Chief Executive Officer. 20+ yrs. global and China local pharma.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 00:33:39.824518+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 21, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Audience Definition", "slug": "audience-definition", "status": "active", "bestFor": null, "canonId": "019dd956-7f2a-775d-aeee-ff099bcb7756", "version": 1, "bodyDocId": null, "description": "Six key questions: Who are they? What do they know? What do they believe? What do they care about? What do they fear? What decisions can they make?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "f6bfbee0-99a7-403c-83a0-3eb3f0a8a339", "evidence": "Board of Directors list with names, titles, and company logos", "pageRefs": null, "priority": "Core", "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:33:26.294819+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 29, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "81f19533-f421-49a4-b4fb-89aacca1b0e9", "evidence": "The slide uses horizontal bars to represent the duration and status of clinical trials across different phases.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:28:38.351+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "frameworkName": "gantt-chart" }, { "matchId": "a5083534-c04a-447b-a44b-a122d260c03f", "evidence": "The slide uses a left-to-right flow to show the mechanism of action.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:28:41.391+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "frameworkName": "process" }, { "matchId": "b96d47bd-805b-4ce4-b9aa-274f0ec3ace7", "evidence": "The circular arrows around the central diagram suggest a self-reinforcing mechanism.", "framework": null, "confidence": 0.7, "extraction": { "at": "2026-05-02 11:28:42.863+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 7, "frameworkName": "flywheel" }, { "matchId": "287e5e13-cff6-4e38-801b-aefca7fcb189", "evidence": "Timeline of transactions", "framework": null, "confidence": 0.6, "extraction": { "at": "2026-05-02 11:28:38.886+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 8, "frameworkName": "gantt-chart" }, { "matchId": "ffda6a9f-4efe-4456-8275-f0781e9d74d4", "evidence": "Comparison of Olvi-Vec against other oncolytic virus assets", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:28:42.181+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "frameworkName": "competitive-advantage" }, { "matchId": "7018bce0-af42-4c03-a385-1ca1a14c63d3", "evidence": "Visual hierarchy of technology evolution", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:28:39.305+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "frameworkName": "pyramid" }, { "matchId": "99336ef0-1504-4f48-b535-b8b270571f19", "evidence": "The slide uses a left-to-right flow to describe the clinical trial progression.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:28:39.973+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "frameworkName": "process" }, { "matchId": "9d4f2f6c-85ac-4606-884a-f2e3809fc5ad", "evidence": "Comparative bar chart and table against industry peers", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:28:40.337+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 17, "frameworkName": "comparison_frame" }, { "matchId": "193a681a-4200-418d-b5f9-c1ee46cebe30", "evidence": "Standard structure for reporting clinical trial protocols (Inclusion criteria, arms, endpoints)", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:28:46.369+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 18, "frameworkName": "clinical-trial-design" }, { "matchId": "ae0a1a2f-3bc5-4134-9d48-c926f9ba31b0", "evidence": "Presents clinical trial data comparing cohorts to demonstrate efficacy", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:28:41.17+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 19, "frameworkName": "evidence-matrix" }, { "matchId": "3af8f0f4-105f-4557-a09c-ee350827bdac", "evidence": "The slide outlines the core pillars of a commercial launch strategy.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:28:42.105+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 26, "frameworkName": "go-to-market-strategy" }, { "matchId": "4af8119b-a652-441d-a54a-8a8a0b85849f", "evidence": "The slide uses a visual arrow to represent future milestones over time.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:28:41.485+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 30, "frameworkName": "timeline" }, { "matchId": "2207dd0e-5cec-4eaf-8d32-296359c83797", "evidence": "The slide contrasts the patient's state before and after Olvi-Vec treatment.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:28:43.542+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 37, "frameworkName": "before-after-bridge" } ], "patterns": [] }, "storymakers": null, "score": null, "review": null, "activistThesis": null, "pitchdeck": { "metadata": null, "profile": null }, "slides": [ { "page": 1, "type": "setup", "title": "Includes company logo, tagline, and date.", "function": "front_matter", "imagePath": "https://imgproxy.kitesheet.com/hd5S-xAiXrjmRNGWfv5TJn9C5dw-OKI1GuKf9ugGBs8/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8zNTJlZTQxNmU2YTk3YTliMzllMTMwOWZhZmRhYjBmMy9wMDAxLmpwZw", "rawType": "cover", "block": null, "metadata": { "slideType": "cover", "slideTypeCanon": { "name": "Cover", "slug": "cover", "status": "active", "canonId": "019de52d-05f2-729d-9f93-e0504f0a2410", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "sparse", "densityScore": 12, "componentCount": 3, "textChars": 70, "nDataPoints": 0, "notes": "Includes company logo, tagline, and date.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:28:37.191+00", "seconds": 1.879, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/1", "deck": "/decks/019de075-f745-744d-a2c3-62fcecd316e9", "deckAnchor": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-1", "deckJson": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json" }, "components": [ { "bbox": { "h": 0.15, "w": 0.45, "x": 0.15, "y": 0.4 }, "kind": "image", "text": "GENELUX", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:37.191+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "54a0ea86-fedc-4b48-8202-84c6bf6bcdc5", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.3, "x": 0.03, "y": 0.93 }, "kind": "paragraph", "text": "Corporate Presentation | October 2023", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:37.191+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1d48ba37-9a48-44ab-9dd3-015414d475d3", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.3, "x": 0.16, "y": 0.57 }, "kind": "paragraph", "text": "Redefining Immuno-Oncology", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:37.191+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "72950679-1eef-4ce3-a73b-63d65cf7ca4a", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 3, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 1, "name": "Problem (Identify pain)", "beatId": "e444b487-fcb2-4bdd-9b87-8dd886121483", "matchId": "c6868580-ab1d-4db0-aaa6-d004c6bcc7ce", "beatType": { "name": "Problem (Identify pain)", "slug": "problem-agitate-solution-problem-identify-pain", "status": "active", "canonId": "019dd9b8-0e78-74bb-b8f6-54348367a131", "version": 1, "description": null }, "evidence": "The initial slides introduce the problem and highlight the limitations of current oncolytic immunotherapies.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "thumbSrc": "https://imgproxy.kitesheet.com/HiCFMiUJaPcB2MEv3-tMliW5f36P25z1E8WYb3ZxJX4/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8zNTJlZTQxNmU2YTk3YTliMzllMTMwOWZhZmRhYjBmMy9wMDAxLmpwZw", "imagePathAlt": "https://imgproxy.kitesheet.com/DTVfwdEfBkZC45tvrz_r12FlpDpUyomE-8INAVPruWM/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8zNTJlZTQxNmU2YTk3YTliMzllMTMwOWZhZmRhYjBmMy9wMDAxLnBuZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/O9Fz_ziPydBMi3ToiAMbGsvbUvL8XNhk3d0A3VyK3E4/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8zNTJlZTQxNmU2YTk3YTliMzllMTMwOWZhZmRhYjBmMy9wMDAxLnBuZw" }, { "page": 2, "type": "setup", "function": "other", "rawType": "disclaimer", "block": null, "metadata": { "slideType": "disclaimer", "slideTypeCanon": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "019de52d-0801-727b-b98a-5ed095aeee78", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "sparse", "densityScore": 13, "componentCount": 2, "textChars": 178, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:28:37.823+00", "seconds": 2.504, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/2", "deck": "/decks/019de075-f745-744d-a2c3-62fcecd316e9", "deckAnchor": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-2", "deckJson": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json" }, "components": [ { "bbox": { "h": 0.785, "w": 0.846, "x": 0.077, "y": 0.145 }, "kind": "disclaimer", "text": "This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933... [full text of legal disclaimer]", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:37.823+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5b28fd06-9845-4656-9cc4-26ed6c5fc533", "parentComponentId": null }, { "bbox": { "h": 0.045, "w": 0.335, "x": 0.077, "y": 0.055 }, "kind": "title", "text": "Forward Looking Statements", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:37.823+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "14e5c1ef-4a39-474e-9e08-d9b148ec5d59", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 3, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 1, "name": "Problem (Identify pain)", "beatId": "e444b487-fcb2-4bdd-9b87-8dd886121483", "matchId": "c6868580-ab1d-4db0-aaa6-d004c6bcc7ce", "beatType": { "name": "Problem (Identify pain)", "slug": "problem-agitate-solution-problem-identify-pain", "status": "active", "canonId": "019dd9b8-0e78-74bb-b8f6-54348367a131", "version": 1, "description": null }, "evidence": "The initial slides introduce the problem and highlight the limitations of current oncolytic immunotherapies.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 3, "type": "resolution", "function": "summarize", "rawType": "key_takeaways", "block": null, "metadata": { "slideType": "key_takeaways", "slideTypeCanon": { "name": "Key takeaways", "slug": "key_takeaways", "status": "active", "canonId": "019de52d-06e7-7674-a891-9f7de3b11b6d", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "dense", "densityScore": 72, "componentCount": 6, "textChars": 755, "nDataPoints": 3, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:28:39.431+00", "seconds": 3.749, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/3", "deck": "/decks/019de075-f745-744d-a2c3-62fcecd316e9", "deckAnchor": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-3", "deckJson": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json" }, "components": [ { "bbox": { "h": 0.15, "w": 0.8, "x": 0.14, "y": 0.47 }, "kind": "list", "text": "Validating Strategic Partnerships. Newsoara Biopharma (Greater China rights) initiated a Phase 1b/2 clinical trial with Olvi-Vec in small-cell lung cancer and ELIAS Animal Health (global rights) is preparing a canine efficacy study with V-VET1", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.431+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0103754e-3332-4294-b586-fea3b833c3ee", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.6, "x": 0.14, "y": 0.78 }, "kind": "list", "text": "Estimated Billion Dollar Plus Annual Market Opportunity in the U.S. Potential beyond this in numerous clinical settings", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.431+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2b632227-c39a-4942-b18e-b11e0e43911e", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.6, "x": 0.14, "y": 0.32 }, "kind": "list", "text": "CHOICE™ Platform; Broad and Diverse Discovery Engine. Library with over 500 novel vaccinia strains and 110+ transgenes", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.431+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "689c0158-6303-4b95-bd27-78490a89b941", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.8, "x": 0.14, "y": 0.17 }, "kind": "list", "text": "Olvi-Vec: De-risked late-stage Clinical Program. Ongoing pivotal trial in late-stage Ovarian Cancer, SCLC and planned Phase 2 trial Adjuvant Maintenance NSCLC", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.431+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "aa256ad9-eb75-4d6f-a221-91e144753e32", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.6, "x": 0.14, "y": 0.65 }, "kind": "list", "text": "Focused Commercial Strategy. US launch in Ovarian Cancer initially; strategic partnerships for ex-US rights", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.431+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bccb1d1c-d327-4483-95d4-9446b5ff9ea5", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.15, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "Highlights", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.431+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2cfbacc0-73bc-4a1b-b746-2d0742788d52", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "cd8bb61a-bff7-4104-8cd8-c051b50b66c8", "evidence": "Validating Strategic Partnerships. Newsoara Biopharma (Greater China rights) initiated a Phase 1b/2 clinical trial with Olvi-Vec in small-cell lung cancer and ELIAS Animal Health (global rights) is preparing", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:33:36.150999+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 3, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 1, "name": "Problem (Identify pain)", "beatId": "e444b487-fcb2-4bdd-9b87-8dd886121483", "matchId": "c6868580-ab1d-4db0-aaa6-d004c6bcc7ce", "beatType": { "name": "Problem (Identify pain)", "slug": "problem-agitate-solution-problem-identify-pain", "status": "active", "canonId": "019dd9b8-0e78-74bb-b8f6-54348367a131", "version": 1, "description": null }, "evidence": "The initial slides introduce the problem and highlight the limitations of current oncolytic immunotherapies.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 4, "type": "resolution", "title": "The slide uses a three-column layout to highlight key value propositions of the Olvi-Vec technology.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 85, "componentCount": 11, "textChars": 1009, "nDataPoints": 0, "notes": "The slide uses a three-column layout to highlight key value propositions of the Olvi-Vec technology.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:28:39.525+00", "seconds": 3.731, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/4", "deck": "/decks/019de075-f745-744d-a2c3-62fcecd316e9", "deckAnchor": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-4", "deckJson": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json" }, "components": [ { "bbox": { "h": 0.15, "w": 0.15, "x": 0.72, "y": 0.25 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.525+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2fc6998f-4804-43df-afe8-5e8c76e34e2f", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.15, "x": 0.13, "y": 0.25 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.525+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8be61602-2cf3-4127-8ae1-cd6288b0d886", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.15, "x": 0.42, "y": 0.25 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.525+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a4daed67-975e-4084-a4fe-b3fc4c14d9d9", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.28, "x": 0.06, "y": 0.58 }, "kind": "list", "text": "Regional and systemic administration to preferentially locate, colonize and destroy tumor cells. In Ovarian Cancer trials, catheter placement is prior to chemotherapy, with removal 2 days after initial placement. IV therapy currently being used in small cell lung cancer Phase 1 trial.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.525+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0c60f732-a820-4cbb-8171-847bf189bc1d", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.28, "x": 0.36, "y": 0.58 }, "kind": "list", "text": "Strong data in Phase 1b/2 study in platinum-resistant/refractory ovarian cancer (PRROC). No Maximum Tolerated Dose (MTD) observed+. Potential utility in multiple cancers (demonstrated in 20 pre-clinical tumor models), including metastatic disease.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.525+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "260319ab-3aec-439a-8e13-8af59ec7e28a", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.28, "x": 0.66, "y": 0.58 }, "kind": "list", "text": "Turns tumors “hot” by localized inflammation and induction of the influx of tumor infiltrating lymphocytes (TILs). Positively modulates anti-tumor pathways in tumor microenvironment.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.525+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b9a41b7e-8468-4509-8278-0d347fb142d0", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.64, "x": 0.18, "y": 0.12 }, "kind": "paragraph", "text": "Olvi-Vec: Engineered to selectively target and eliminate tumor cells while inducing a robust patient-specific immune response", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.525+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ac4d4302-0fc3-4d4e-b5ea-21421a53283c", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.28, "x": 0.06, "y": 0.48 }, "kind": "title", "text": "Physician-preferred Routes of Delivery", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.525+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "69cb9037-ad65-45b1-8709-828af1b17747", "parentComponentId": null }, { "bbox": { "h": 0.07, "w": 0.85, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "The Most Advanced Non-local Delivery Oncolytic Immunotherapy", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.525+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "addff008-fd84-4cfd-9b7c-0480bf26ed96", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.28, "x": 0.36, "y": 0.48 }, "kind": "title", "text": "Antitumor Effect and Well Tolerated", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.525+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c300c9a3-5b0b-4ad1-91ed-c0f7d838f38c", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.28, "x": 0.66, "y": 0.48 }, "kind": "title", "text": "Ideal Backbone of Combination Therapy", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.525+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e1205397-c783-4379-b86a-a0e02c5a7444", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 9, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 4, "name": "Agitate (Make it worse)", "beatId": "fdbee508-b41b-482b-8db8-5d1f0a14e7b6", "matchId": "c6868580-ab1d-4db0-aaa6-d004c6bcc7ce", "beatType": { "name": "Agitate (Make it worse)", "slug": "problem-agitate-solution-agitate-make-it-worse", "status": "active", "canonId": "019dd9b8-0f5a-71dd-bae7-8fadb0d09456", "version": 1, "description": null }, "evidence": "Slides 4-9 emphasize the complications and challenges of current treatments, including resistance and refractoriness.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Development", "slug": "development", "status": "active", "canonId": "019dd9b8-0332-7008-b3aa-11b0840a57b1", "version": 1, "description": "The middle stretch in arcs that have one. Often where length problems creep in." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 9, "from": 4, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "38515402-0f9a-4e9b-81f7-00348eb645d5", "evidence": "The deck highlights the limitations and challenges of current treatments, implicitly raising the question of what if we don't innovate.", "position": 0, "objective": "What if we don't adopt a new approach to oncolytic immunotherapy?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:38:33.915904+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 5, "type": "resolution", "title": "The slide uses a Gantt-style visualization to show clinical trial stages for multiple drug candidates.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "sparse", "densityScore": 20, "componentCount": 3, "textChars": 208, "nDataPoints": 0, "notes": "The slide uses a Gantt-style visualization to show clinical trial stages for multiple drug candidates.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:28:38.351+00", "seconds": 2.496, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/5", "deck": "/decks/019de075-f745-744d-a2c3-62fcecd316e9", "deckAnchor": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-5", "deckJson": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.4, "x": 0.4, "y": 0.2 }, "kind": "chart", "text": "Clinical trial progress bars", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Horizontal bar chart", "slug": "bar-horizontal", "status": "active", "canonId": "019de52c-fec4-7221-986b-1cb5f5e84b1f", "version": 1, "description": null }, "framework": null }, "subkind": "bar-horizontal", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:38.351+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "18b471da-94d2-477b-bc90-9973b5334292", "parentComponentId": null }, { "bbox": { "h": 0.78, "w": 0.96, "x": 0.02, "y": 0.13 }, "kind": "table", "text": "Pipeline table with columns: Olvi-Vec, Human Health, Design, Preclinical, Phase 1, Phase 2, Phase 3, Collaborators", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:38.351+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bff43e69-8656-4191-b19f-cc4809b74cb6", "parentComponentId": null }, { "bbox": { "h": 0.07, "w": 0.85, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "Diversified Designs and Indications Exploit Competitive Advantages", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:38.351+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b16e4d80-faa4-4b25-b972-caae9479afd1", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "597ce2da-bc5d-4aa2-9957-2231e7cbb8a0", "evidence": "Pipeline table with columns: Olvi-Vec, Human Health, Design, Preclinical, Phase 1, Phase 2, Phase 3, Collaborators", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:33:32.323187+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "81f19533-f421-49a4-b4fb-89aacca1b0e9", "evidence": "The slide uses horizontal bars to represent the duration and status of clinical trials across different phases.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:28:38.351+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "frameworkName": "gantt-chart" } ], "arcBeats": [ { "to": 9, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 4, "name": "Agitate (Make it worse)", "beatId": "fdbee508-b41b-482b-8db8-5d1f0a14e7b6", "matchId": "c6868580-ab1d-4db0-aaa6-d004c6bcc7ce", "beatType": { "name": "Agitate (Make it worse)", "slug": "problem-agitate-solution-agitate-make-it-worse", "status": "active", "canonId": "019dd9b8-0f5a-71dd-bae7-8fadb0d09456", "version": 1, "description": null }, "evidence": "Slides 4-9 emphasize the complications and challenges of current treatments, including resistance and refractoriness.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Development", "slug": "development", "status": "active", "canonId": "019dd9b8-0332-7008-b3aa-11b0840a57b1", "version": 1, "description": "The middle stretch in arcs that have one. Often where length problems creep in." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 9, "from": 4, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "38515402-0f9a-4e9b-81f7-00348eb645d5", "evidence": "The deck highlights the limitations and challenges of current treatments, implicitly raising the question of what if we don't innovate.", "position": 0, "objective": "What if we don't adopt a new approach to oncolytic immunotherapy?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:38:33.915904+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 6, "type": "resolution", "title": "Uses a process diagram to illustrate the transition from cold to hot tumor states via viral infection.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "balanced", "densityScore": 43, "componentCount": 4, "textChars": 494, "nDataPoints": 0, "notes": "Uses a process diagram to illustrate the transition from cold to hot tumor states via viral infection.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:28:41.391+00", "seconds": 5.442, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/6", "deck": "/decks/019de075-f745-744d-a2c3-62fcecd316e9", "deckAnchor": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-6", "deckJson": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json" }, "components": [ { "bbox": { "h": 0.4, "w": 0.6, "x": 0.35, "y": 0.25 }, "kind": "diagram", "text": "Olvi-Vec viral infection leads to oncolysis, innate immune activation, and adaptive immune activation.", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.391+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "86f0b577-9a62-4713-bb3c-956c3c2fa3a5", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.25, "x": 0.05, "y": 0.22 }, "kind": "list", "text": "Olvi-Vec is a robust immune modulator that utilizes a triple mode of action to mount a personalized attack against cancer cells throughout the body. Kills cancer cells directly. Enhances (neo)antigen presentation. Converts tumor microenvironment.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.391+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e6735930-3011-46b4-98f0-def1498813f6", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.6, "x": 0.35, "y": 0.55 }, "kind": "table", "text": "'Cold' tumor before Olvi-Vec vs 'Hot' tumor following Olvi-Vec immunotherapy", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.391+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c8473cf2-7cba-44cd-9607-cdbc10a52730", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.94, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "Selective Replication In Tumors Unleashes Immune System Against Cancer", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.391+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a442c08c-1ce3-46c4-9ea5-bfe38e4fa9b6", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "a5083534-c04a-447b-a44b-a122d260c03f", "evidence": "The slide uses a left-to-right flow to show the mechanism of action.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:28:41.391+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "frameworkName": "process" } ], "arcBeats": [ { "to": 9, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 4, "name": "Agitate (Make it worse)", "beatId": "fdbee508-b41b-482b-8db8-5d1f0a14e7b6", "matchId": "c6868580-ab1d-4db0-aaa6-d004c6bcc7ce", "beatType": { "name": "Agitate (Make it worse)", "slug": "problem-agitate-solution-agitate-make-it-worse", "status": "active", "canonId": "019dd9b8-0f5a-71dd-bae7-8fadb0d09456", "version": 1, "description": null }, "evidence": "Slides 4-9 emphasize the complications and challenges of current treatments, including resistance and refractoriness.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Development", "slug": "development", "status": "active", "canonId": "019dd9b8-0332-7008-b3aa-11b0840a57b1", "version": 1, "description": "The middle stretch in arcs that have one. Often where length problems creep in." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 9, "from": 4, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "38515402-0f9a-4e9b-81f7-00348eb645d5", "evidence": "The deck highlights the limitations and challenges of current treatments, implicitly raising the question of what if we don't innovate.", "position": 0, "objective": "What if we don't adopt a new approach to oncolytic immunotherapy?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:38:33.915904+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 7, "type": "resolution", "title": "The central diagram shows a biological mechanism comparing 'Absence of Effector T Cells' (Platinum resistant) vs 'Presence of Effector T Cells' (Platinum sensit", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 50, "componentCount": 5, "textChars": 456, "nDataPoints": 0, "notes": "The central diagram shows a biological mechanism comparing 'Absence of Effector T Cells' (Platinum resistant) vs 'Presence of Effector T Cells' (Platinum sensitive).", "elementsJson": null, "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:28:42.863+00", "seconds": 6.679, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/7", "deck": "/decks/019de075-f745-744d-a2c3-62fcecd316e9", "deckAnchor": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-7", "deckJson": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json" }, "components": [ { "bbox": { "h": 0.03, "w": 0.23, "x": 0.385, "y": 0.2 }, "kind": "callout", "text": "Olvi-Vec-Induced Hot Tumor", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:42.863+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "10a08bf5-6b3f-495c-a1eb-fed1d4ffbbb5", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.18, "x": 0.41, "y": 0.33 }, "kind": "image", "text": "Biological mechanism diagram", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:42.863+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "06fa7c84-97c3-4589-a1ca-cfae33b874c6", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.26, "x": 0.69, "y": 0.365 }, "kind": "list", "text": "Chemotherapy synergy: Immunogenic cell death; Depletion of suppressor cells; Increase susceptibility to cytotoxic T-lymphocytes", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:42.863+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "33d83d5e-17dd-47e5-a7d2-d7a03e511a87", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.26, "x": 0.08, "y": 0.365 }, "kind": "list", "text": "Pro-therapeutic gene expression: Positive regulation of T-cell activating and trafficking; Expression profiles correlated to better prognosis in cancer patients; Promotion of sensitization/response to chemotherapy", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:42.863+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ed6e826b-e14d-4a66-83f7-02263acb7871", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.94, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "Olvi-Vec-Primed Immunochemotherapy: Overcoming Drug Resistance", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:42.863+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9dffc990-ab62-4cff-8db1-be1913640558", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "b96d47bd-805b-4ce4-b9aa-274f0ec3ace7", "evidence": "The circular arrows around the central diagram suggest a self-reinforcing mechanism.", "framework": null, "confidence": 0.7, "extraction": { "at": "2026-05-02 11:28:42.863+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 7, "frameworkName": "flywheel" } ], "arcBeats": [ { "to": 9, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 4, "name": "Agitate (Make it worse)", "beatId": "fdbee508-b41b-482b-8db8-5d1f0a14e7b6", "matchId": "c6868580-ab1d-4db0-aaa6-d004c6bcc7ce", "beatType": { "name": "Agitate (Make it worse)", "slug": "problem-agitate-solution-agitate-make-it-worse", "status": "active", "canonId": "019dd9b8-0f5a-71dd-bae7-8fadb0d09456", "version": 1, "description": null }, "evidence": "Slides 4-9 emphasize the complications and challenges of current treatments, including resistance and refractoriness.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Development", "slug": "development", "status": "active", "canonId": "019dd9b8-0332-7008-b3aa-11b0840a57b1", "version": 1, "description": "The middle stretch in arcs that have one. Often where length problems creep in." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 9, "from": 4, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "38515402-0f9a-4e9b-81f7-00348eb645d5", "evidence": "The deck highlights the limitations and challenges of current treatments, implicitly raising the question of what if we don't innovate.", "position": 0, "objective": "What if we don't adopt a new approach to oncolytic immunotherapy?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:38:33.915904+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 8, "type": "evidence", "title": "The slide uses a timeline to establish market maturity and investor confidence.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 56, "componentCount": 4, "textChars": 609, "nDataPoints": 15, "notes": "The slide uses a timeline to establish market maturity and investor confidence.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:28:38.886+00", "seconds": 2.681, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/8", "deck": "/decks/019de075-f745-744d-a2c3-62fcecd316e9", "deckAnchor": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-8", "deckJson": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json" }, "components": [ { "bbox": { "h": 0.4, "w": 0.9, "x": 0.05, "y": 0.5 }, "kind": "chart", "text": "Timeline of transactions from 2011 to 2023", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": null, "framework": null }, "subkind": "timeline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:38.886+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0d31748b-c664-4d32-ae07-392e715ca225", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.4, "x": 0.06, "y": 0.15 }, "kind": "list", "text": "Emerging Late-Stage Modality: With its recent IPO, Genelux joined the public markets as a Phase 3 company. A maturing field with Amgen launching Imlygic in 2014 and Phase 3 companies working to validate its power and potential.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:38.886+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "084da863-b1b5-4dbd-8d9a-78685c29b690", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.45, "x": 0.52, "y": 0.15 }, "kind": "list", "text": "CG Oncology raises aggregate $225 million in Series E and crossover financing for clinical-stage uro-onc pipeline. Replimune completed a $225 million offering as well as $200M in non-dilutive debt financing. Genelux enters the public markets raising $68.5M in the first half of 2023.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:38.886+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bd9475e2-e7b6-4215-9092-80b13632d987", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "Over $4 Billion in Transactions in Active Oncolytic Space", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:38.886+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f194938f-f7d4-434b-bc5a-24907c349ae6", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "287e5e13-cff6-4e38-801b-aefca7fcb189", "evidence": "Timeline of transactions", "framework": null, "confidence": 0.6, "extraction": { "at": "2026-05-02 11:28:38.886+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 8, "frameworkName": "gantt-chart" } ], "arcBeats": [ { "to": 9, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 4, "name": "Agitate (Make it worse)", "beatId": "fdbee508-b41b-482b-8db8-5d1f0a14e7b6", "matchId": "c6868580-ab1d-4db0-aaa6-d004c6bcc7ce", "beatType": { "name": "Agitate (Make it worse)", "slug": "problem-agitate-solution-agitate-make-it-worse", "status": "active", "canonId": "019dd9b8-0f5a-71dd-bae7-8fadb0d09456", "version": 1, "description": null }, "evidence": "Slides 4-9 emphasize the complications and challenges of current treatments, including resistance and refractoriness.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Development", "slug": "development", "status": "active", "canonId": "019dd9b8-0332-7008-b3aa-11b0840a57b1", "version": 1, "description": "The middle stretch in arcs that have one. Often where length problems creep in." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 9, "from": 4, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "38515402-0f9a-4e9b-81f7-00348eb645d5", "evidence": "The deck highlights the limitations and challenges of current treatments, implicitly raising the question of what if we don't innovate.", "position": 0, "objective": "What if we don't adopt a new approach to oncolytic immunotherapy?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:38:33.915904+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 9, "type": "setup", "title": "The slide uses a list-based comparison and a logo-grid to frame the competitive landscape.", "function": "compare_peers", "rawType": "competitive_analysis", "block": null, "metadata": { "slideType": "competitive_analysis", "slideTypeCanon": { "name": "Competitive analysis", "slug": "competitive_analysis", "status": "active", "canonId": "019de52d-093e-776b-94c6-c1573f5f1a31", "version": 1, "description": null }, "function": "compare_peers", "functionCanon": { "name": "Compare peers", "slug": "compare_peers", "status": "active", "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630", "version": 1, "description": null }, "density": "dense", "densityScore": 57, "componentCount": 5, "textChars": 669, "nDataPoints": 0, "notes": "The slide uses a list-based comparison and a logo-grid to frame the competitive landscape.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:28:42.181+00", "seconds": 5.854, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/9", "deck": "/decks/019de075-f745-744d-a2c3-62fcecd316e9", "deckAnchor": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-9", "deckJson": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json" }, "components": [ { "bbox": { "h": 0.4, "w": 0.2, "x": 0.36, "y": 0.35 }, "kind": "image", "text": "Genelux, Amgen, Replimune, CG Oncology, Daiichi-Sankyo, Oncolytics Biotech", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo grid", "slug": "logo-grid", "status": "active", "canonId": "019de52c-fdd7-7409-93e5-81280a8ca215", "version": 1, "description": null }, "framework": null }, "subkind": "logo-grid", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:42.181+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "00d8261a-475b-4bc0-8f0c-599cb064da7b", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.3, "x": 0.65, "y": 0.35 }, "kind": "list", "text": "Target & Treat Metastatic Disease; Systemic Delivery and redosing; Robust Immune Activation Profile; Target & Treat Tumors of Various Size", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:42.181+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "517e2cf0-8214-4924-8d53-783b4674b88a", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.25, "x": 0.06, "y": 0.3 }, "kind": "list", "text": "Broad spectrum of activity; Tumor selectivity; Strong lytic activity / spread; Strong immune activator; Engineering capability; Multiple routes of delivery; Nonhuman pathogen; Stable DNA virus; Cytoplasmic, no genomic integration", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:42.181+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dda86efa-d699-486a-8e77-049f00555a02", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.6, "x": 0.35, "y": 0.75 }, "kind": "paragraph", "text": "IV dosing is the physician preferred administration technique, and our IV data has the potential to enable physician preferred administration vs. local-delivery-only assets", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:42.181+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "65ca8180-d811-4542-969a-b6fe359a3bdd", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.6, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "Competitive Advantages of Olvi-Vec as an Oncolytic Virus", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:42.181+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4bb4f1be-2c86-4c7d-bb21-0eeffd6ed43a", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "ffda6a9f-4efe-4456-8275-f0781e9d74d4", "evidence": "Comparison of Olvi-Vec against other oncolytic virus assets", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:28:42.181+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "frameworkName": "competitive-advantage" } ], "arcBeats": [ { "to": 9, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 4, "name": "Agitate (Make it worse)", "beatId": "fdbee508-b41b-482b-8db8-5d1f0a14e7b6", "matchId": "c6868580-ab1d-4db0-aaa6-d004c6bcc7ce", "beatType": { "name": "Agitate (Make it worse)", "slug": "problem-agitate-solution-agitate-make-it-worse", "status": "active", "canonId": "019dd9b8-0f5a-71dd-bae7-8fadb0d09456", "version": 1, "description": null }, "evidence": "Slides 4-9 emphasize the complications and challenges of current treatments, including resistance and refractoriness.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Development", "slug": "development", "status": "active", "canonId": "019dd9b8-0332-7008-b3aa-11b0840a57b1", "version": 1, "description": "The middle stretch in arcs that have one. Often where length problems creep in." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 9, "from": 4, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "38515402-0f9a-4e9b-81f7-00348eb645d5", "evidence": "The deck highlights the limitations and challenges of current treatments, implicitly raising the question of what if we don't innovate.", "position": 0, "objective": "What if we don't adopt a new approach to oncolytic immunotherapy?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:38:33.915904+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 10, "type": "setup", "title": "The slide uses a pyramid diagram to represent the evolution of oncolytic virus technology, with Genelux's platform at the top.", "function": "present_solution", "rawType": "unfair_advantage", "block": null, "metadata": { "slideType": "unfair_advantage", "slideTypeCanon": { "name": "Unfair advantage", "slug": "unfair_advantage", "status": "active", "canonId": "019de52d-0f56-744f-8bb4-c8a8cca240d6", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 60, "componentCount": 5, "textChars": 576, "nDataPoints": 2, "notes": "The slide uses a pyramid diagram to represent the evolution of oncolytic virus technology, with Genelux's platform at the top.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:28:39.305+00", "seconds": 2.968, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/10", "deck": "/decks/019de075-f745-744d-a2c3-62fcecd316e9", "deckAnchor": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-10", "deckJson": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json" }, "components": [ { "bbox": { "h": 0.7, "w": 0.45, "x": 0.22, "y": 0.15 }, "kind": "diagram", "text": "Pyramid showing 7 completed clinical trials, ~150 patients, and key technical advantages like Systemic Dosing and Robust Immune Activation.", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Pyramid", "slug": "pyramid", "status": "active", "canonId": "019de52d-043b-715a-b3a3-780976e14c5c", "version": 1, "description": null }, "framework": null }, "subkind": "pyramid", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.305+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cbc87403-6b38-4a4f-b14b-cbfead95ad6f", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.2, "x": 0.03, "y": 0.28 }, "kind": "image", "text": "Genelux logo", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.305+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "afc60a97-92e6-4b2e-98cd-92a77d3db221", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.28, "x": 0.68, "y": 0.75 }, "kind": "subtitle", "text": "Commercial/Late-stage 1st Generation viruses confirm modality's potential, but all are limited to local delivery and scope of addressable cancers", "attrs": null, "canon": { "kind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "82d821ee-2793-42e7-8f16-c6131385a3ce", "version": 1, "description": "Header-zone supporting text near the title (= ex body.description with bbox)." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.305+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "73fac451-1557-4b15-85df-7893f143f8fd", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.28, "x": 0.68, "y": 0.25 }, "kind": "subtitle", "text": "Olvi-Vec has the potential to redefine the oncolytic virus space and provide utility across multiple tumor types by enabling physician-preferred administration techniques and setting new benchmarks in efficacy and safety.", "attrs": null, "canon": { "kind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "82d821ee-2793-42e7-8f16-c6131385a3ce", "version": 1, "description": "Header-zone supporting text near the title (= ex body.description with bbox)." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.305+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bd70caa8-383f-4247-8b14-72a3b9a79630", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.8, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "Creating a New Paradigm Of Oncolytic Virus Drug Development", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.305+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "aa6bd6b7-8712-4df6-bcf6-29fd83653252", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "7018bce0-af42-4c03-a385-1ca1a14c63d3", "evidence": "Visual hierarchy of technology evolution", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:28:39.305+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "frameworkName": "pyramid" } ], "arcBeats": [ { "to": 38, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 10, "name": "Solution (Provide relief)", "beatId": "523d1cf4-1cd0-4572-8561-e435ff7a2275", "matchId": "c6868580-ab1d-4db0-aaa6-d004c6bcc7ce", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 10-38 present Olvi-Vec as a solution, detailing its competitive advantages, clinical results, and market potential.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 11, "type": "evidence", "title": "The slide uses a document-style callout for key takeaways and a vertical icon-list for clinical data points.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 86, "componentCount": 8, "textChars": 959, "nDataPoints": 6, "notes": "The slide uses a document-style callout for key takeaways and a vertical icon-list for clinical data points.", "elementsJson": null, "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:28:39.613+00", "seconds": 3.178, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/11", "deck": "/decks/019de075-f745-744d-a2c3-62fcecd316e9", "deckAnchor": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-11", "deckJson": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json" }, "components": [ { "bbox": { "h": 0.75, "w": 0.26, "x": 0.04, "y": 0.185 }, "kind": "callout", "text": "Key Clinical Takeaways", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.613+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b6e1143c-a76b-4144-a253-606cba0c5e68", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.4, "x": 0.51, "y": 0.2 }, "kind": "list", "text": "Patient Background & Study Treatment: Heavily pre-treated PRROC patients with documented progressive disease. Cohort 1 received a Single cycle of intraperitoneal delivery on 2 consecutive days; total dose: 6x10^9 pfu, same dose as PhII/III", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.613+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "38433deb-839a-499e-afde-4e9d673ccb7d", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.4, "x": 0.51, "y": 0.72 }, "kind": "list", "text": "Translational Evidence: Activation of tumor-specific T cell response detected in blood", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.613+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3e9cd72f-5a27-4567-9dd9-1552a6138be2", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.25, "x": 0.05, "y": 0.33 }, "kind": "list", "text": "mPFS of 6.1 months (median 4 prior lines; 95%CI: 2.2-NA) for the six patients in Cohort 1 virus monotherapy – the dose used in Ph2- SOC-AURELIA regimen (1-2 prior lines; mPFS: 6.7 mos) ELAHARE (1-3 prior lines; mPFS: 5.62 mos). Cohort 2/3 dosing done exponentially higher with no MTD reached.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.613+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4bc7984b-4e9c-4eff-ada3-feafda803211", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.4, "x": 0.51, "y": 0.38 }, "kind": "list", "text": "Tolerability: No Dose Limiting Toxicity (DLT), No Maximum Tolerated Dose (MTD), No Grade 4 Adverse Events (AE)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.613+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9eea5cf8-cbda-4f50-b3fb-4877ffa65978", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.4, "x": 0.51, "y": 0.55 }, "kind": "list", "text": "Antitumor activity: Clinical Benefit Rate: 73% (8/11), 4/11 patients had >2x PFS relative to immediate prior chemotherapy", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.613+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c4fd8473-f5e0-46e8-9ff8-b0df0716cd25", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.25, "x": 0.57, "y": 0.135 }, "kind": "title", "text": "Olvi-Vec Monotherapy", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.613+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "112fb523-0c54-4c87-9730-94f0a657b127", "parentComponentId": null }, { "bbox": { "h": 0.07, "w": 0.94, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "Phase 1b: Anti-tumor Activity as Monotherapy Leading into Combination", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.613+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8369f7eb-c731-45ea-acfc-88220fb1c774", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 38, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 10, "name": "Solution (Provide relief)", "beatId": "523d1cf4-1cd0-4572-8561-e435ff7a2275", "matchId": "c6868580-ab1d-4db0-aaa6-d004c6bcc7ce", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 10-38 present Olvi-Vec as a solution, detailing its competitive advantages, clinical results, and market potential.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 12, "type": "evidence", "title": "The slide uses a process-flow layout to show the trial design and its validation through publications and follow-up trials.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 79, "componentCount": 7, "textChars": 900, "nDataPoints": 1, "notes": "The slide uses a process-flow layout to show the trial design and its validation through publications and follow-up trials.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:28:39.973+00", "seconds": 3.502, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/12", "deck": "/decks/019de075-f745-744d-a2c3-62fcecd316e9", "deckAnchor": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-12", "deckJson": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json" }, "components": [ { "bbox": { "h": 0.15, "w": 0.27, "x": 0.72, "y": 0.56 }, "kind": "callout", "text": "OnPrime Phase 3 Trial: Ongoing Pivotal Phase 3 for the treatment of PRROC patients, using the same Experimental Arm treatment regimen", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.973+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5e66f381-7379-43d3-922d-34dff42e42ca", "parentComponentId": null }, { "bbox": { "h": 0.42, "w": 0.42, "x": 0.28, "y": 0.29 }, "kind": "diagram", "text": "Interventional Single Group Assignment n=27; Design: Olvi-Vec via intraperitoneal infusion; Endpoints: Primary (mPFS, ORR, CA-125), Secondary (mOS)", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.973+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "18557f98-382c-42eb-be52-08175b222c6c", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.25, "x": 0.02, "y": 0.435 }, "kind": "list", "text": "High-grade serous, endometrioid or clear-cell ovarian cancer which includes: platinum-resistant or PRROC with at least two prior lines of therapy; ECOG Performance status is at 0 or 1", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.973+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f565da1e-8b36-441f-9e74-f917972e16da", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.35, "x": 0.35, "y": 0.79 }, "kind": "paragraph", "text": "Results of the VIRO-15 Phase 2 Trial were published in JAMA Oncology (Link)", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.973+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0c0d77ba-3465-4148-a54f-c571db2f687e", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.27, "x": 0.72, "y": 0.25 }, "kind": "table", "text": "Data Presentations: 1. 2020 Digital Annual Meeting of International Gynecologic Cancer Society (Oral Plenary Session); 2. JAMA Oncology (Selected for Journal podcast series interview)", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.973+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b79c8fcc-20f1-4a43-8aae-75d35834bcd2", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.7, "x": 0.15, "y": 0.14 }, "kind": "title", "text": "Olvi-Vec Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.973+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "07fa3dc9-6ca5-4989-b3ac-90f2c9f13e56", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.78, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "Completed Phase 2 Tested Olvi-Vec Immunochemotherapy", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.973+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f52b376d-073b-4cc6-ad3c-93fdeda6d903", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "4d0b6645-d797-4a21-a80f-3702d1bd3a49", "evidence": "table/data: Data Presentations: 1. 2020 Digital Annual Meeting of International Gynecologic Cancer Society (Oral Plenary Session); 2. JAMA Oncology (Selected for Journal podcast series interview)", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:33:32.606235+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "99336ef0-1504-4f48-b535-b8b270571f19", "evidence": "The slide uses a left-to-right flow to describe the clinical trial progression.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:28:39.973+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "frameworkName": "process" } ], "arcBeats": [ { "to": 38, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 10, "name": "Solution (Provide relief)", "beatId": "523d1cf4-1cd0-4572-8561-e435ff7a2275", "matchId": "c6868580-ab1d-4db0-aaa6-d004c6bcc7ce", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 10-38 present Olvi-Vec as a solution, detailing its competitive advantages, clinical results, and market potential.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 13, "type": "evidence", "title": "Data table presents ORR, Duration of Response, CA-125 response, PFS, and OS across patient subgroups.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 70, "componentCount": 5, "textChars": 986, "nDataPoints": 15, "notes": "Data table presents ORR, Duration of Response, CA-125 response, PFS, and OS across patient subgroups.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:28:40.242+00", "seconds": 3.537, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/13", "deck": "/decks/019de075-f745-744d-a2c3-62fcecd316e9", "deckAnchor": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-13", "deckJson": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.25, "x": 0.04, "y": 0.215 }, "kind": "callout", "text": "Key Clinical Takeaways", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:40.242+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c7cca283-a43d-4641-b8bd-eb833cfc1385", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.48, "x": 0.48, "y": 0.7 }, "kind": "disclaimer", "text": "*Baseline for ORR & PFS evaluation is the timepoint immediately prior to starting post-Olvi-Vec carboplatin doublet +/- bevacizumab to allow direct comparison to historical data or patients' own previous line of chemotherapy. **Eligible for evaluation: with at least 1 measurable target lesion at baseline; including 2 patients without post-chemo scan after virotherapy, and therefore are assigned to the 'inevaluable for response' category per RECIST1.1. ^Including 3 unconfirmed; 2 in resistant and 1 in refractory groups", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:40.242+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6d5b416a-7173-43ca-a8fd-f5ece0b0bb06", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.25, "x": 0.05, "y": 0.3 }, "kind": "list", "text": "Promising ORR and PFS, and clinical reversal of platinum resistance and refractoriness among patients with PRROC. All patients had documented progressive disease at enrollment. Overall response rate in 27 patients was 54% with 7.6-month median duration of response. Historical PFS in this patient population is ~4 mos", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:40.242+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d1b9bc7c-ca63-4069-b144-40c6946aadcd", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.6, "x": 0.36, "y": 0.275 }, "kind": "table", "text": "Overall Response Rate (ORR) & Progression-Free Survival (PFS)*", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:40.242+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b0a1a042-0099-4caa-9d75-477248ee8af3", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.8, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "Clinically-Meaningful Responses in Heavily Pretreated Patients", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:40.242+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "51804e45-6741-4394-bd66-5e4c02033722", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "db8e05a9-e4aa-4ae5-ac3e-669b215c078b", "evidence": "table/data: Overall Response Rate (ORR) & Progression-Free Survival (PFS)*", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:33:32.678177+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 38, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 10, "name": "Solution (Provide relief)", "beatId": "523d1cf4-1cd0-4572-8561-e435ff7a2275", "matchId": "c6868580-ab1d-4db0-aaa6-d004c6bcc7ce", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 10-38 present Olvi-Vec as a solution, detailing its competitive advantages, clinical results, and market potential.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 14, "type": "evidence", "title": "Waterfall plot and spider plot showing patient-level clinical outcomes.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "balanced", "densityScore": 46, "componentCount": 4, "textChars": 366, "nDataPoints": 12, "notes": "Waterfall plot and spider plot showing patient-level clinical outcomes.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:28:39.203+00", "seconds": 2.382, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/14", "deck": "/decks/019de075-f745-744d-a2c3-62fcecd316e9", "deckAnchor": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-14", "deckJson": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json" }, "components": [ { "bbox": { "h": 0.35, "w": 0.6, "x": 0.35, "y": 0.12 }, "kind": "chart", "text": "Tumor Shrinkage Waterfall Plot", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.203+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a51a2d38-dd01-4f9e-a3e6-44eb4e60305e", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.6, "x": 0.35, "y": 0.52 }, "kind": "chart", "text": "Duration of Response Spider Plot", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.203+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3094ddc2-d10f-4909-bdd1-5d71c4eb12e3", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.3, "x": 0.05, "y": 0.3 }, "kind": "list", "text": "Overall, 86% of PRROC patients showed tumor reduction, with 91% of Platinum-refractory patients showing tumor reduction. Four patients had 100% reduction. DOR of 7.6 Months in all platinum-Resistant patients. DOR of 8.0 Months in platinum-refractory patients.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.203+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d38426c0-45ca-4c7a-9cad-aa94c37c5b4e", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "Demonstrated Deep and Durable Tumor Shrinkage", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.203+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "eea8c3c9-5d92-44cd-a818-f59d5f344235", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 38, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 10, "name": "Solution (Provide relief)", "beatId": "523d1cf4-1cd0-4572-8561-e435ff7a2275", "matchId": "c6868580-ab1d-4db0-aaa6-d004c6bcc7ce", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 10-38 present Olvi-Vec as a solution, detailing its competitive advantages, clinical results, and market potential.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 15, "type": "evidence", "title": "The slide uses a series of bar charts to compare PFS across multiple treatment regimens for three specific patients (15B-01, 15B-15, 15B-17).", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 62, "componentCount": 6, "textChars": 359, "nDataPoints": 24, "notes": "The slide uses a series of bar charts to compare PFS across multiple treatment regimens for three specific patients (15B-01, 15B-15, 15B-17).", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:28:39.715+00", "seconds": 2.888, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/15", "deck": "/decks/019de075-f745-744d-a2c3-62fcecd316e9", "deckAnchor": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-15", "deckJson": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json" }, "components": [ { "bbox": { "h": 0.35, "w": 0.28, "x": 0.36, "y": 0.568 }, "kind": "chart", "text": "PFS comparison for patient 15B-15", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.715+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "72b0ae6d-fefe-4a17-aff1-daa6a63da8ba", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.28, "x": 0.03, "y": 0.568 }, "kind": "chart", "text": "PFS comparison for patient 15B-01", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.715+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9cc3660f-f8fd-4cc3-9cfb-4b4a9e03f3dc", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.28, "x": 0.69, "y": 0.568 }, "kind": "chart", "text": "PFS comparison for patient 15B-17", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.715+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c612d148-2adb-417f-8e99-eae0cede898c", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.9, "x": 0.05, "y": 0.2 }, "kind": "list", "text": "Patient profiles (15B-01, 15B-15, 15B-17) including stage, ECOG score, and biomarker status.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.715+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "de295075-0671-4a1b-9232-39e56cd1f9ee", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.8, "x": 0.08, "y": 0.09 }, "kind": "title", "text": "Exemplary platinum-refractory patients, after platinum re-challenge, achieved PFS exceeding any prior lines", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.715+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0f962c98-d6dd-459b-8bad-e072bdce7789", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.85, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "Olvi-Vec-Primed Immunochemotherapy Overcomes \"Refractoriness\"", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:39.715+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bd87a4db-6684-415f-ac8a-3ac12c0fed51", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 38, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 10, "name": "Solution (Provide relief)", "beatId": "523d1cf4-1cd0-4572-8561-e435ff7a2275", "matchId": "c6868580-ab1d-4db0-aaa6-d004c6bcc7ce", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 10-38 present Olvi-Vec as a solution, detailing its competitive advantages, clinical results, and market potential.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 16, "type": "evidence", "title": "Kaplan-Meier survival curve showing superior performance of VIRO-15 compared to historical 4th line treatment data.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 60, "componentCount": 5, "textChars": 484, "nDataPoints": 12, "notes": "Kaplan-Meier survival curve showing superior performance of VIRO-15 compared to historical 4th line treatment data.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:28:40.83+00", "seconds": 3.473, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/16", "deck": "/decks/019de075-f745-744d-a2c3-62fcecd316e9", "deckAnchor": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-16", "deckJson": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json" }, "components": [ { "bbox": { "h": 0.06, "w": 0.3, "x": 0.65, "y": 0.46 }, "kind": "callout", "text": "Durable Benefit: ~ 20% long-term survivors (median follow-up time: 47.0 mos)", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:40.83+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4081c31f-7ec2-41d6-9a4e-f3681ee4b367", "parentComponentId": null }, { "bbox": { "h": 0.75, "w": 0.6, "x": 0.35, "y": 0.15 }, "kind": "chart", "text": "Kaplan-Meier survival curve showing OS proportion over months", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:40.83+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3fe01db1-d44b-4741-a104-4f8b0aab9871", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.28, "x": 0.04, "y": 0.185 }, "kind": "list", "text": "Key Clinical Takeaways: 20% long-term survivors consistent with commercially successful immunotherapies. Historical data in 4th line shows 9.8 mos mOS. VIRO-15 achieved 15.7 mos mOS. 4 of 6 long-term survivors were platinum-refractory.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:40.83+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1d847cca-f7c3-4140-a7ff-07b743a01c21", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.33, "x": 0.635, "y": 0.115 }, "kind": "table", "text": "Historical Data vs VIRO-15 comparison table", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:40.83+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8f5c3194-c227-4328-8f59-e985a14ca06b", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.85, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "Durable Benefit of Overall Survival via Clinically-Validated Endpoint", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:40.83+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7caa6e93-0299-4e45-bc15-b9d0ea9bf098", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 38, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 10, "name": "Solution (Provide relief)", "beatId": "523d1cf4-1cd0-4572-8561-e435ff7a2275", "matchId": "c6868580-ab1d-4db0-aaa6-d004c6bcc7ce", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 10-38 present Olvi-Vec as a solution, detailing its competitive advantages, clinical results, and market potential.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 17, "type": "resolution", "title": "The chart compares cross-trial data; the footnote explicitly warns against direct comparison due to protocol differences.", "function": "summarize", "rawType": "key_takeaways", "block": null, "metadata": { "slideType": "key_takeaways", "slideTypeCanon": { "name": "Key takeaways", "slug": "key_takeaways", "status": "active", "canonId": "019de52d-06e7-7674-a891-9f7de3b11b6d", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "dense", "densityScore": 72, "componentCount": 6, "textChars": 726, "nDataPoints": 3, "notes": "The chart compares cross-trial data; the footnote explicitly warns against direct comparison due to protocol differences.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:28:40.337+00", "seconds": 2.92, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/17", "deck": "/decks/019de075-f745-744d-a2c3-62fcecd316e9", "deckAnchor": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-17", "deckJson": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json" }, "components": [ { "bbox": { "h": 0.2, "w": 0.58, "x": 0.365, "y": 0.245 }, "kind": "chart", "text": "Comparative efficacy chart across RECIST1.1, CA-125, and PFS-6-month metrics.", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Grouped bar chart", "slug": "bar-grouped", "status": "active", "canonId": "019de52c-ff3b-751e-a8ff-f21ff11097b1", "version": 1, "description": null }, "framework": null }, "subkind": "bar-grouped", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:40.337+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c6b807a4-369c-4c0d-ba7c-556344cdb04a", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.29, "x": 0.045, "y": 0.31 }, "kind": "list", "text": "Olvi-Vec trial inclusion criteria allows patients regardless of (i) tumor biomarkers, (ii) platinum refractory tumors, or (iii) number of prior lines of treatment (i.e., no cap). Olvi-Vec Phase 2 results approach results in less pre-treated platinum-sensitive patients", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:40.337+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1ec7e18f-7087-4a5a-93ce-47dea08c52da", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.56, "x": 0.38, "y": 0.15 }, "kind": "paragraph", "text": "While clinical remissions are obtainable, a majority of patients will relapse. Genelux looks to take an all-comers approach", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:40.337+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6ae36887-2231-4705-81e4-09e7815b2f16", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.58, "x": 0.365, "y": 0.8 }, "kind": "source-note", "text": "References (1)-(6) and disclaimer footnote regarding cross-trial comparison limitations.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:40.337+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f1eed1ea-727e-478c-b2ff-9a8271d69d24", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.58, "x": 0.365, "y": 0.47 }, "kind": "table", "text": "Study comparison table listing prior lines of treatment and regimens for various clinical trials.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:40.337+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fe0b1d69-09c3-4387-945a-7f71f31fdb1e", "parentComponentId": null }, { "bbox": { "h": 0.07, "w": 0.94, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "“Allcomers” Approach May Reset Life Clock of Heavily Pre-treated Patients", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:40.337+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "18993078-2d9e-4ef6-93ec-c97c0b2f4571", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Audience Definition", "slug": "audience-definition", "status": "active", "bestFor": null, "canonId": "019dd956-7f2a-775d-aeee-ff099bcb7756", "version": 1, "bodyDocId": null, "description": "Six key questions: Who are they? What do they know? What do they believe? What do they care about? What do they fear? What decisions can they make?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "8a3c282d-8ac3-4e52-a6d1-ef4c0c5be02c", "evidence": "Olvi-Vec addresses a broad and underserved pool of patients", "pageRefs": null, "priority": "Core", "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:33:39.483357+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 17, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Problem Statement Canvas", "slug": "problem-statement-canvas", "status": "active", "bestFor": null, "canonId": "019dd956-839d-744b-ad11-9bf3e3642a18", "version": 1, "bodyDocId": null, "description": "Structured definition of the problem: What? Who? Where? When? Scale?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "fe0ebe8f-6ecf-4c2a-9bd1-8ee92844061d", "evidence": "Olvi-Vec trial inclusion criteria allows patients regardless of (i) tumor biomarkers, (ii) platinum refractory tumors, or (iii) number of prior lines of treatment", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.6, "extraction": { "at": "2026-07-17 00:33:39.521344+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 17, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "9d4f2f6c-85ac-4606-884a-f2e3809fc5ad", "evidence": "Comparative bar chart and table against industry peers", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:28:40.337+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 17, "frameworkName": "comparison_frame" } ], "arcBeats": [ { "to": 38, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 10, "name": "Solution (Provide relief)", "beatId": "523d1cf4-1cd0-4572-8561-e435ff7a2275", "matchId": "c6868580-ab1d-4db0-aaa6-d004c6bcc7ce", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 10-38 present Olvi-Vec as a solution, detailing its competitive advantages, clinical results, and market potential.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 18, "type": "resolution", "title": "The slide outlines a clinical trial protocol for Olvi-Vec in ovarian cancer.", "function": "plan_implementation", "rawType": "appendix_methodology", "block": null, "metadata": { "slideType": "appendix_methodology", "slideTypeCanon": { "name": "Appendix methodology", "slug": "appendix_methodology", "status": "active", "canonId": "019de52d-07d9-726c-8599-167f2d2ffaa7", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "dense", "densityScore": 73, "componentCount": 6, "textChars": 858, "nDataPoints": 2, "notes": "The slide outlines a clinical trial protocol for Olvi-Vec in ovarian cancer.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:28:46.369+00", "seconds": 8.881, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/18", "deck": "/decks/019de075-f745-744d-a2c3-62fcecd316e9", "deckAnchor": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-18", "deckJson": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.56, "x": 0.22, "y": 0.078 }, "kind": "callout", "text": "A platinum resensitizing agent is a long-standing desirable and highly demanded mechanism of action of Gvn-Oncs. their so-call “Holy Grail”.*", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:46.369+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "79acfecc-3075-4d10-9f0f-e97481ee950a", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.42, "x": 0.29, "y": 0.29 }, "kind": "diagram", "text": "Multi-center, randomized open-label n=186. Experimental Arm: Olvi-Vec + Platinum-doublet + Bevacizumab. Active Comparator Arm: Platinum-doublet + Bevacizumab.", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:46.369+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "90039ba2-a8bc-42c1-ab5c-3d97c5ab1976", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.26, "x": 0.02, "y": 0.36 }, "kind": "list", "text": "High-grade serous, endometrioid, or clear-cell ovarian cancer. Platinum-resistant or -refractory disease. Received prior bevacizumab (or biosimilar) treatment. Received a minimum of 3 prior lines of systemic therapy. ECOG 0 or 1.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:46.369+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "92b6e312-cc27-4847-b926-bf7f2010de95", "parentComponentId": null }, { "bbox": { "h": 0.07, "w": 0.72, "x": 0.14, "y": 0.13 }, "kind": "paragraph", "text": "Trial design intends to replicate previous data showing anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the tumor microenvironment", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:46.369+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "64101f49-5217-46c1-80a0-f2c23a62ab0f", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.26, "x": 0.73, "y": 0.028 }, "kind": "table", "text": "Primary Endpoint: Progression-Free Survival. Key Secondary Endpoints: Treatment-emergent AEs, DOR, ORR, OS.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "KPI table", "slug": "kpi", "status": "active", "canonId": "019de52d-0324-7799-a84e-d0885a8ad400", "version": 1, "description": null }, "framework": null }, "subkind": "kpi", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:46.369+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "518a31c5-8f73-465c-8115-4590aab378d5", "parentComponentId": null }, { "bbox": { "h": 0.07, "w": 0.94, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "Phase 3 Pivotal Trial Design Founded on Phase 2 Trial Design & Results", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:46.369+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f813f456-404c-493d-8034-47591ffee360", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "2x2 matrix", "slug": "matrix-2x2", "status": "active", "bestFor": null, "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8", "version": 1, "bodyDocId": null, "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "adb3a46b-052b-4ccd-8d22-f7ccf893e231", "evidence": "Experimental Arm: Olvi-Vec + Platinum-doublet + Bevacizumab. Active Comparator Arm: Platinum-doublet + Bevacizumab", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 00:33:39.597741+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 18, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "193a681a-4200-418d-b5f9-c1ee46cebe30", "evidence": "Standard structure for reporting clinical trial protocols (Inclusion criteria, arms, endpoints)", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:28:46.369+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 18, "frameworkName": "clinical-trial-design" } ], "arcBeats": [ { "to": 38, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 10, "name": "Solution (Provide relief)", "beatId": "523d1cf4-1cd0-4572-8561-e435ff7a2275", "matchId": "c6868580-ab1d-4db0-aaa6-d004c6bcc7ce", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 10-38 present Olvi-Vec as a solution, detailing its competitive advantages, clinical results, and market potential.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 19, "type": "resolution", "title": "Includes Kaplan-Meier survival curves and dose escalation scatter plots for two distinct patient groups.", "function": "show_traction", "rawType": "key_takeaways", "block": null, "metadata": { "slideType": "key_takeaways", "slideTypeCanon": { "name": "Key takeaways", "slug": "key_takeaways", "status": "active", "canonId": "019de52d-06e7-7674-a891-9f7de3b11b6d", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 55, "componentCount": 4, "textChars": 586, "nDataPoints": 12, "notes": "Includes Kaplan-Meier survival curves and dose escalation scatter plots for two distinct patient groups.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:28:41.17+00", "seconds": 3.337, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/19", "deck": "/decks/019de075-f745-744d-a2c3-62fcecd316e9", "deckAnchor": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-19", "deckJson": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.65, "x": 0.33, "y": 0.25 }, "kind": "chart", "text": "Kaplan-Meier survival curves and dose escalation plots", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.17+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9fcbef01-e7e6-4280-a353-d4b5e9ae1373", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.28, "x": 0.04, "y": 0.25 }, "kind": "list", "text": "Demonstrated feasibility and clinical benefit of multiple IV cycles; Median 5 prior lines of therapy; Regimen: various dosing levels and schedules; Well tolerated: no-MTD reached with one DLT; Clinical Benefit: statistically significant OS benefit", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.17+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9c252695-d2f5-4fba-802c-0040ab6bba14", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.65, "x": 0.33, "y": 0.65 }, "kind": "paragraph", "text": "Group A (n=11; lower-dose group) vs Group B (n=11; higher-dose group). Median OS 4.6 months vs 16.8 months (p=0.026). Group A (n=5; lowest-dose) vs Group B (n=5; highest-dose). Median OS 4.6 months vs 20.9 months (p=0.002).", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.17+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7d752772-d7f5-4d21-a3fa-1d2f5d9da52d", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.85, "x": 0.02, "y": 0.03 }, "kind": "title", "text": "Systemic administration demonstrated dose-dependent OS benefit", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.17+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "735b9cbb-08a3-40cb-b01a-b808311db00d", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Chart Selection Guide", "slug": "chart-selection-guide", "status": "active", "bestFor": null, "canonId": "019dd956-b1a0-700b-ba17-0e16c4d5bcae", "version": 1, "bodyDocId": null, "description": "Choosing the right chart type for your data and message", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "31baa5e5-0a3d-4e89-8302-286dbde027c8", "evidence": "Kaplan-Meier survival curves and dose escalation plots", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:33:39.67477+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 19, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "ae0a1a2f-3bc5-4134-9d48-c926f9ba31b0", "evidence": "Presents clinical trial data comparing cohorts to demonstrate efficacy", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:28:41.17+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 19, "frameworkName": "evidence-matrix" } ], "arcBeats": [ { "to": 38, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 10, "name": "Solution (Provide relief)", "beatId": "523d1cf4-1cd0-4572-8561-e435ff7a2275", "matchId": "c6868580-ab1d-4db0-aaa6-d004c6bcc7ce", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 10-38 present Olvi-Vec as a solution, detailing its competitive advantages, clinical results, and market potential.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 20, "type": "evidence", "title": "Includes specific patient case reports (Pt #21A-06 and Pt #21A-04) as evidence of efficacy.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 55, "componentCount": 5, "textChars": 398, "nDataPoints": 8, "notes": "Includes specific patient case reports (Pt #21A-06 and Pt #21A-04) as evidence of efficacy.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:28:41.471+00", "seconds": 3.566, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/20", "deck": "/decks/019de075-f745-744d-a2c3-62fcecd316e9", "deckAnchor": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-20", "deckJson": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json" }, "components": [ { "bbox": { "h": 0.2, "w": 0.15, "x": 0.68, "y": 0.47 }, "kind": "chart", "text": "Best change (%) of target lesion sizes from baseline by RECIST Wk 7", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.471+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0b1ddcc0-d227-430e-ae5f-ccf26f7929b5", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.15, "x": 0.445, "y": 0.47 }, "kind": "chart", "text": "SLD of nontarget lesions (mm)", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.471+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "02c46501-600c-4978-a010-4d9b3dc9e1bf", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.28, "x": 0.04, "y": 0.215 }, "kind": "list", "text": "Key Trial Takeaways: Anti-tumor effect of IV Immunochemotherapy; High and Condensed Dosing; Well tolerated; Monotherapy; Combination therapy", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.471+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "935ea2ea-227f-429a-88d1-709f73b55b50", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.5, "x": 0.38, "y": 0.24 }, "kind": "paragraph", "text": "Recurrent metastatic cervical cancer with lung mets; High-grade pancreatic cancer with lung & liver mets", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.471+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8b9e6d0c-b731-4711-97c0-e4547d7eb613", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.8, "x": 0.02, "y": 0.02 }, "kind": "title", "text": "Systemic Administration + Chemo Generated Encouraging Data", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.471+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5c3d09c3-65db-4822-b39b-f3fc14a8f090", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Data Story Arc", "slug": "data-story-arc", "status": "active", "bestFor": null, "canonId": "019dd956-9c30-728e-b974-d3fb123dcf5a", "version": 1, "bodyDocId": null, "description": "Context → Conflict → Insight → Implication structure for data narratives", "familyLabel": null, "categoryName": "Loop", "categorySlug": "loop" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "47d87a43-7bea-4f96-8892-82f54357e873", "evidence": "Key Trial Takeaways: Anti-tumor effect of IV Immunochemotherapy; High and Condensed Dosing; Well tolerated; Monotherapy; Combination therapy", "pageRefs": null, "priority": "Core", "whenToUse": null, "confidence": 0.6, "extraction": { "at": "2026-07-17 00:33:39.749834+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 20, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 38, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 10, "name": "Solution (Provide relief)", "beatId": "523d1cf4-1cd0-4572-8561-e435ff7a2275", "matchId": "c6868580-ab1d-4db0-aaa6-d004c6bcc7ce", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 10-38 present Olvi-Vec as a solution, detailing its competitive advantages, clinical results, and market potential.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 21, "type": "evidence", "title": "Includes a bio for Benny Li, PhD, CEO of Newsoara.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 88, "componentCount": 10, "textChars": 676, "nDataPoints": 7, "notes": "Includes a bio for Benny Li, PhD, CEO of Newsoara.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:28:41.555+00", "seconds": 3.53, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/21", "deck": "/decks/019de075-f745-744d-a2c3-62fcecd316e9", "deckAnchor": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-21", "deckJson": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json" }, "components": [ { "bbox": { "h": 0.15, "w": 0.15, "x": 0.08, "y": 0.63 }, "kind": "image", "text": "Benny Li, PhD", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.555+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e88dcedb-c58d-4822-b1eb-2e7ae0857e0b", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.4, "x": 0.05, "y": 0.0015 }, "kind": "image", "text": "Genelux and Newsoara logos", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo grid", "slug": "logo-grid", "status": "active", "canonId": "019de52c-fdd7-7409-93e5-81280a8ca215", "version": 1, "description": null }, "framework": null }, "subkind": "logo-grid", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.555+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "56ad3317-4acc-4521-84dd-5965a2c919f5", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.15, "x": 0.66, "y": 0.5 }, "kind": "metric", "text": "Top 10 Blue-chip Biotech Investors", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.555+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "16dc78a4-8f61-4c3d-8307-fdf02ddcfb9f", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.15, "x": 0.84, "y": 0.5 }, "kind": "metric", "text": "2023 IPO Planned", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.555+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "434f734e-128e-40bc-822f-3cec56fcda77", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.15, "x": 0.75, "y": 0.25 }, "kind": "metric", "text": "5 Phase IIb/III, 2 Phase II", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.555+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "73f1be74-f114-406a-ae2b-50cc7d634aa4", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.15, "x": 0.48, "y": 0.5 }, "kind": "metric", "text": "$850 Million Valuation", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.555+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "98d2f83e-c94b-4b49-b0cd-0cf32ae87431", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.15, "x": 0.57, "y": 0.25 }, "kind": "metric", "text": "7 Pipelines, 12 Indications", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.555+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ac562b49-c153-4118-8791-95c5054ac783", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.5, "x": 0.46, "y": 0.78 }, "kind": "paragraph", "text": "Newsoara has paid $11M to date and GNLX is eligible for additional development, regulatory and sales milestone payments and up to mid-double-digit percentages royalties on net sales", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.555+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4a6b57aa-f58d-401e-8559-d7fa46394375", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.25, "x": 0.17, "y": 0.63 }, "kind": "paragraph", "text": "Benny Li, PhD, Founder and Chief Executive Officer. 20+ yrs. global and China local pharma. Former VP, GM of Takeda China Development Center and SVP, Executive GM of R&D at Hansoh Pharmaceuticals. Former Head of Clinical Development & Medical Affairs in Asia at Alcon/Novartis", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.555+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "62639946-381e-4972-a502-5276dae9fe0e", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.6, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "Genelux has Partnered with Newsoara BioPharma Co., Ltd", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.555+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c5ddad03-d33c-438a-bf44-0256069f2024", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Authority citation", "slug": "authority-citation", "status": "active", "bestFor": null, "canonId": "019dd9e1-49ae-7557-89ad-3fca70469b45", "version": 1, "bodyDocId": null, "description": "Quoting an authority figure, study, or precedent to lend weight.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "7054fa26-8532-4cef-bb5a-bed41ee1b307", "evidence": "Benny Li, PhD, Founder and Chief Executive Officer. 20+ yrs. global and China local pharma.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 00:33:39.824518+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 21, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 38, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 10, "name": "Solution (Provide relief)", "beatId": "523d1cf4-1cd0-4572-8561-e435ff7a2275", "matchId": "c6868580-ab1d-4db0-aaa6-d004c6bcc7ce", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 10-38 present Olvi-Vec as a solution, detailing its competitive advantages, clinical results, and market potential.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 22, "type": "evidence", "title": "The slide highlights a strategic partnership, funding, and commercial rights split between US and Greater China markets.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 52, "componentCount": 4, "textChars": 573, "nDataPoints": 4, "notes": "The slide highlights a strategic partnership, funding, and commercial rights split between US and Greater China markets.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:28:41.107+00", "seconds": 2.959, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/22", "deck": "/decks/019de075-f745-744d-a2c3-62fcecd316e9", "deckAnchor": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-22", "deckJson": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json" }, "components": [ { "bbox": { "h": 0.4, "w": 0.28, "x": 0.05, "y": 0.22 }, "kind": "list", "text": "Newsoara will fund the US-based Genelux Phase 2 trial in NSCLC; Newsoara has development and commercialization rights in Greater China; Interim readout for one or more systemic administration trials expected as early as mid-2024", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.107+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ba33934f-695a-400a-a0ca-919513cccb6a", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.45, "x": 0.48, "y": 0.68 }, "kind": "paragraph", "text": "Genelux will have worldwide commercial rights (excluding Greater China) to all data generated from clinical trials of Olvi-Vec in China.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.107+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "edc04535-cb33-4b59-acac-22a1964b84c4", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.55, "x": 0.36, "y": 0.25 }, "kind": "table", "text": "Systemic Program: Clinical Trials table with columns for Sponsor, Trial Sites, Indication, Clinical Stage, Patients, Randomization, and Status.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.107+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e82eb44b-85fe-460b-820f-0d05fe453746", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.8, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "Validating Industry Collaboration with Newsoara BioPharma Co., Ltd", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.107+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a3b103d5-b741-45e9-afc4-112901ce0043", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 38, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 10, "name": "Solution (Provide relief)", "beatId": "523d1cf4-1cd0-4572-8561-e435ff7a2275", "matchId": "c6868580-ab1d-4db0-aaa6-d004c6bcc7ce", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 10-38 present Olvi-Vec as a solution, detailing its competitive advantages, clinical results, and market potential.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 23, "type": "resolution", "title": "The slide highlights a combination therapy approach involving oncolytic immunotherapy and adoptive cell therapy.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 66, "componentCount": 5, "textChars": 998, "nDataPoints": 2, "notes": "The slide highlights a combination therapy approach involving oncolytic immunotherapy and adoptive cell therapy.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:28:41.29+00", "seconds": 3.106, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/23", "deck": "/decks/019de075-f745-744d-a2c3-62fcecd316e9", "deckAnchor": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-23", "deckJson": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.28, "x": 0.04, "y": 0.22 }, "kind": "list", "text": "V2ACT Immunotherapy, combines an oncolytic immunotherapy and adoptive cell therapy. Induces an acute inflammatory response in the tumor and converts tumor microenvironment from immunosuppressive to immunostimulatory; Anticipated to enhance effect of neoantigen specific effector T cells", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.29+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a229b67e-1349-4988-85d8-b31da355231d", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.62, "x": 0.35, "y": 0.22 }, "kind": "paragraph", "text": "V2ACT Therapeutics is a joint venture between Genelux Corporation and TVAX Biomedical, Inc. established to develop and test V2ACT. Vaccination increases the numbers of neoantigen-specific T cells in the body and Olvi-Vec kills cancer cells and potentiates T cells by increasing cancer tissue receptivity to adoptively transferred neoantigen-specific effector T cells.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.29+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7fb9259e-d410-4d0a-85ff-0c2e186a9a26", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.62, "x": 0.35, "y": 0.74 }, "kind": "source-note", "text": "Novel IO modality: United States Patent No. 11,633,442, issued in April 2023", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.29+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6a5fa367-00f6-4716-88f2-2535cd0da056", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.62, "x": 0.35, "y": 0.45 }, "kind": "table", "text": "Technology | TVI Adoptive Cell Therapy | Olvi-Vec Oncolytic Immunotherapy; Patients Dosed | ~ 130 | ~ 150; Regulatory | Fast Track Designation / FDA Grant - glioblastoma | Phase 3 enrolling - ovarian", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.29+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e4afa11d-01b0-4388-ae2d-98ce7a3581c7", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.94, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "V2ACT Therapeutics LLC: Joint Venture between GNLX and TVAX BioMedical", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.29+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1084ed66-fe6b-4c7f-b15e-72045530677a", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 38, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 10, "name": "Solution (Provide relief)", "beatId": "523d1cf4-1cd0-4572-8561-e435ff7a2275", "matchId": "c6868580-ab1d-4db0-aaa6-d004c6bcc7ce", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 10-38 present Olvi-Vec as a solution, detailing its competitive advantages, clinical results, and market potential.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 24, "type": "resolution", "title": "The slide uses a map of the US as a background to anchor the market sizing to a specific geography.", "function": "size_opportunity", "rawType": "market_sizing", "block": null, "metadata": { "slideType": "market_sizing", "slideTypeCanon": { "name": "Market sizing", "slug": "market_sizing", "status": "active", "canonId": "019de52d-08c8-756c-8664-733b73a7ee7b", "version": 1, "description": null }, "function": "size_opportunity", "functionCanon": { "name": "Size opportunity", "slug": "size_opportunity", "status": "active", "canonId": "019de52d-147b-7568-8828-a74a27697618", "version": 1, "description": null }, "density": "dense", "densityScore": 69, "componentCount": 6, "textChars": 568, "nDataPoints": 4, "notes": "The slide uses a map of the US as a background to anchor the market sizing to a specific geography.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:28:41.289+00", "seconds": 2.905, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/24", "deck": "/decks/019de075-f745-744d-a2c3-62fcecd316e9", "deckAnchor": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-24", "deckJson": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json" }, "components": [ { "bbox": { "h": 0.45, "w": 0.35, "x": 0.615, "y": 0.115 }, "kind": "callout", "text": "Ovarian Cancer Market ~ $1.8B in 2022, expected CAGR growth ~23.5%. ~236,511 women in the US currently. 70-80% will relapse.", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.289+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "33ab195e-02f4-4374-b84b-e288db83510e", "parentComponentId": null }, { "bbox": { "h": 0.7, "w": 0.45, "x": 0.03, "y": 0.15 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Map", "slug": "map", "status": "active", "canonId": "019de52c-fe4d-77bd-b0a4-d72d58b9e5a4", "version": 1, "description": null }, "framework": null }, "subkind": "map", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.289+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cdf7523f-c2af-425c-ab5b-64ce99e0d2a9", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.3, "x": 0.18, "y": 0.38 }, "kind": "list", "text": "Additional revenue drivers: Re-treatment, Front-Line therapy, Additional Indications, i.e.: Small Cell Lung Cancer, Pancreatic Cancer", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.289+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2942bdab-2603-4f97-b8fe-02ff5b4b25e9", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.4, "x": 0.58, "y": 0.7 }, "kind": "paragraph", "text": "Drivers of Market Penetration: The Phase 3 population is a broad category of patients with significant unmet medical need, including those excluded from other therapies or trials.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.289+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f57b9426-b08b-45be-b6a6-2a6fddc3d110", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.2, "x": 0.14, "y": 0.94 }, "kind": "source-note", "text": "1. Polaris Market Research 2. NIH Ovarian Cancer Fact Sheet", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.289+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b4f1b78b-b1ac-4375-87b3-22bfa242645d", "parentComponentId": null }, { "bbox": { "h": 0.07, "w": 0.94, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "Estimated Billion Dollar Plus annual Olvi-Vec Commercial Opportunity (US)", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.289+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dd75f0b7-77c3-43b9-afbc-79d08e1f9fa2", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 38, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 10, "name": "Solution (Provide relief)", "beatId": "523d1cf4-1cd0-4572-8561-e435ff7a2275", "matchId": "c6868580-ab1d-4db0-aaa6-d004c6bcc7ce", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 10-38 present Olvi-Vec as a solution, detailing its competitive advantages, clinical results, and market potential.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 26, "from": 24, "loop": { "name": "53_jobs_to_be_done", "slug": "53-jobs-to-be-done", "status": "active", "bestFor": "Product innovation, market entry, competitive positioning", "canonId": "019dd956-7b6c-7594-b5b3-eecbe0ab48e8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying", "familyLabel": null }, "matchId": "392920d4-0517-46aa-a9c2-4fb0dd0c15fd", "evidence": "The deck discusses the market opportunity and commercial potential of Olvi-Vec, highlighting its potential to address unmet needs.", "position": 1, "objective": "How can Olvi-Vec address the needs of patients and healthcare systems?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:38:33.951008+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 25, "type": "appendix", "title": "The slide highlights physical assets and operational capacity.", "function": "present_solution", "rawType": "other", "block": null, "metadata": { "slideType": "other", "slideTypeCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-0af5-71ed-83de-d51ae245fc43", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 71, "componentCount": 6, "textChars": 731, "nDataPoints": 1, "notes": "The slide highlights physical assets and operational capacity.", "elementsJson": null, "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:28:41.203+00", "seconds": 2.644, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/25", "deck": "/decks/019de075-f745-744d-a2c3-62fcecd316e9", "deckAnchor": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-25", "deckJson": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json" }, "components": [ { "bbox": { "h": 0.3, "w": 0.25, "x": 0.68, "y": 0.255 }, "kind": "image", "text": "Manufacturing Facility San Diego, CA, USA", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.203+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "03facd15-2063-4506-8bfa-d453a21029cb", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.25, "x": 0.42, "y": 0.255 }, "kind": "image", "text": "Headquarters Westlake Village, CA, USA", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.203+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2b61a0c4-bff9-44af-9e9d-f79de2050e38", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.36, "x": 0.49, "y": 0.535 }, "kind": "image", "text": "Research and Development San Diego, CA, USA", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.203+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "806c1145-0e3f-4bc6-b639-c5ca5411f09c", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.28, "x": 0.05, "y": 0.225 }, "kind": "list", "text": "Established and equipped an independent, Company-controlled 7,500+ Sq. Ft manufacturing facility in San Diego to secure material for pivotal studies and potential commercial supply. cGMP material manufactured and released for the ongoing Phase 3 Trial and Newsoara's trials. Planned investment to augment internal development capabilities as well as continually improve proprietary manufacturing processes. Genelux aims to meet worldwide clinical trial demand and U.S. commercial launch", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.203+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "50330fcc-8d2e-4694-9a4a-f142727432c9", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.4, "x": 0.47, "y": 0.88 }, "kind": "paragraph", "text": "Facilities and Operations: Based in Southern California", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.203+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ce0f36e2-7ef3-490d-b640-4c1ec6a1ef7d", "parentComponentId": null }, { "bbox": { "h": 0.07, "w": 0.94, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "Integrated R&D and Manufacturing Capabilities For Phase 3 And Launch", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.203+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b5cb7b10-165d-4f7d-b272-44f6edc33d8b", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 38, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 10, "name": "Solution (Provide relief)", "beatId": "523d1cf4-1cd0-4572-8561-e435ff7a2275", "matchId": "c6868580-ab1d-4db0-aaa6-d004c6bcc7ce", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 10-38 present Olvi-Vec as a solution, detailing its competitive advantages, clinical results, and market potential.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 26, "from": 24, "loop": { "name": "53_jobs_to_be_done", "slug": "53-jobs-to-be-done", "status": "active", "bestFor": "Product innovation, market entry, competitive positioning", "canonId": "019dd956-7b6c-7594-b5b3-eecbe0ab48e8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying", "familyLabel": null }, "matchId": "392920d4-0517-46aa-a9c2-4fb0dd0c15fd", "evidence": "The deck discusses the market opportunity and commercial potential of Olvi-Vec, highlighting its potential to address unmet needs.", "position": 1, "objective": "How can Olvi-Vec address the needs of patients and healthcare systems?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:38:33.951008+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 26, "type": "resolution", "title": "The slide uses a hub-and-spoke style layout to show the four pillars supporting the central launch strategy.", "function": "plan_implementation", "rawType": "go_to_market", "block": null, "metadata": { "slideType": "go_to_market", "slideTypeCanon": { "name": "Go-to-market", "slug": "go_to_market", "status": "active", "canonId": "019de52d-0ff6-713a-bd55-53d4e90b2304", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "dense", "densityScore": 67, "componentCount": 6, "textChars": 782, "nDataPoints": 0, "notes": "The slide uses a hub-and-spoke style layout to show the four pillars supporting the central launch strategy.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:28:42.105+00", "seconds": 3.369, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/26", "deck": "/decks/019de075-f745-744d-a2c3-62fcecd316e9", "deckAnchor": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-26", "deckJson": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json" }, "components": [ { "bbox": { "h": 0.07, "w": 0.5, "x": 0.25, "y": 0.135 }, "kind": "callout", "text": "Self Launch Olvi-Vec for Ovarian Cancer in the US", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:42.105+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "76977340-9f80-4bc1-b3e7-122008296b2a", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.2, "x": 0.07, "y": 0.35 }, "kind": "list", "text": "Partnerships: Leverage partnership with GOG Foundation. Preeminent US-based cooperative group in Gynecologic Oncology. Composed of leading KOLs in the field. Partners in the OnPrime/GOG-3076 Phase 3 registration trial.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:42.105+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "493fcb20-83c6-4952-b003-3ea59460ab1b", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.2, "x": 0.3, "y": 0.35 }, "kind": "list", "text": "Self-Manufacturing: Large-Scale cGMP Manufacturing. Control of Production Schedule. Attractive COGs. Ability to scale up modular process.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:42.105+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "76c85ec1-787e-4b21-abc8-bebef8c70214", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.2, "x": 0.76, "y": 0.35 }, "kind": "list", "text": "Reimbursement: Compelling Value Proposition for Payors. Significant unmet medical need. No SOC. Combination with generic/biosimilars.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:42.105+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "81ae72ad-681b-44b9-9303-32b203c90034", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.2, "x": 0.53, "y": 0.35 }, "kind": "list", "text": "Patients: Population without Standard of Care. PRROC patients lack effective SoC therapies. Limited number of Gyn-Oncs enabling specialty sales team. Label expansion starting with IV administration in 2L ovarian (Ph2 planned).", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:42.105+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e4978203-1d79-4d52-b556-1b49943c71e2", "parentComponentId": null }, { "bbox": { "h": 0.07, "w": 0.3, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "Commercial Strategy", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:42.105+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4b857d5d-60e0-4023-8968-fe23998d96d2", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "3af8f0f4-105f-4557-a09c-ee350827bdac", "evidence": "The slide outlines the core pillars of a commercial launch strategy.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:28:42.105+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 26, "frameworkName": "go-to-market-strategy" } ], "arcBeats": [ { "to": 38, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 10, "name": "Solution (Provide relief)", "beatId": "523d1cf4-1cd0-4572-8561-e435ff7a2275", "matchId": "c6868580-ab1d-4db0-aaa6-d004c6bcc7ce", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 10-38 present Olvi-Vec as a solution, detailing its competitive advantages, clinical results, and market potential.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 26, "from": 24, "loop": { "name": "53_jobs_to_be_done", "slug": "53-jobs-to-be-done", "status": "active", "bestFor": "Product innovation, market entry, competitive positioning", "canonId": "019dd956-7b6c-7594-b5b3-eecbe0ab48e8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying", "familyLabel": null }, "matchId": "392920d4-0517-46aa-a9c2-4fb0dd0c15fd", "evidence": "The deck discusses the market opportunity and commercial potential of Olvi-Vec, highlighting its potential to address unmet needs.", "position": 1, "objective": "How can Olvi-Vec address the needs of patients and healthcare systems?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:38:33.951008+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 27, "type": "resolution", "title": "The slide categorizes the platform's capabilities into therapeutic genes, immune modularity, and therapeutic antibodies, emphasizing non-GMO status and GLP tox ", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 50, "componentCount": 4, "textChars": 529, "nDataPoints": 2, "notes": "The slide categorizes the platform's capabilities into therapeutic genes, immune modularity, and therapeutic antibodies, emphasizing non-GMO status and GLP tox readiness.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:28:44.812+00", "seconds": 6.065, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/27", "deck": "/decks/019de075-f745-744d-a2c3-62fcecd316e9", "deckAnchor": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-27", "deckJson": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json" }, "components": [ { "bbox": { "h": 0.04, "w": 0.35, "x": 0.63, "y": 0.17 }, "kind": "callout", "text": "In vitro & in vivo tested: GLP Tox ready", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:44.812+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ae503a67-0ace-4eb3-bfa1-d8ea99d6aa96", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.3, "x": 0.65, "y": 0.22 }, "kind": "list", "text": "Immune Modularity Molecules: IL-6/sIL-6R, IL-24; Cell Growth & Differentiation Regulators: BMP-4; Cell Matrix-Degradative Genes: hMMP9; Clonal Isolated Strains: LIVP1.1.1, LIVP5.1.1, V-VET1, Cop15.1.1; Single-Chain Antibodies: Anti-VEGF, Anti-PD-1, Anti-FAP, Anti-PD-L1, Anti-DLL4, Anti-CTLA4, Anti-avb3-integrin", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:44.812+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "12320e6d-defa-4a33-b532-110671c6c918", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.35, "x": 0.15, "y": 0.21 }, "kind": "paragraph", "text": "Engineered and selected clonal isolated (non-GMO) viral strains identified from in vitro and in vivo selection criteria", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:44.812+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6fce4f1e-9901-4aca-b906-731fd3276092", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.7, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "Choice Platform Library: 500+ Vectors with 110+ Transgenes", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:44.812+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "74f8177b-39f7-40e1-914a-f1efd4ef776b", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 38, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 10, "name": "Solution (Provide relief)", "beatId": "523d1cf4-1cd0-4572-8561-e435ff7a2275", "matchId": "c6868580-ab1d-4db0-aaa6-d004c6bcc7ce", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 10-38 present Olvi-Vec as a solution, detailing its competitive advantages, clinical results, and market potential.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 28, "type": "setup", "title": "The slide highlights key defensive moats including patent counts, expiration dates, and lack of royalty obligations.", "function": "present_solution", "rawType": "unfair_advantage", "block": null, "metadata": { "slideType": "unfair_advantage", "slideTypeCanon": { "name": "Unfair advantage", "slug": "unfair_advantage", "status": "active", "canonId": "019de52d-0f56-744f-8bb4-c8a8cca240d6", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 57, "componentCount": 6, "textChars": 335, "nDataPoints": 2, "notes": "The slide highlights key defensive moats including patent counts, expiration dates, and lack of royalty obligations.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:28:44.965+00", "seconds": 5.963, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/28", "deck": "/decks/019de075-f745-744d-a2c3-62fcecd316e9", "deckAnchor": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-28", "deckJson": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.25, "x": 0.67, "y": 0.28 }, "kind": "callout", "text": "Strong IP & Regulatory Designations", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:44.965+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f0bacbab-663b-49c8-bfce-cc33724b6d5b", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.07, "x": 0.08, "y": 0.28 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Icon grid", "slug": "icon-grid", "status": "active", "canonId": "019de52c-fdfe-749d-9990-1db465a3eed4", "version": 1, "description": null }, "framework": null }, "subkind": "icon-grid", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:44.965+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "74b52b8d-22b4-47cd-af76-30b8f327237b", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.35, "x": 0.16, "y": 0.51 }, "kind": "list", "text": "Olvi-Vec: Worldwide operating freedom;\nNo third-party royalties due", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:44.965+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4e7405c3-5dba-4de4-8a9e-d7b8fe8b020a", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.35, "x": 0.16, "y": 0.28 }, "kind": "list", "text": "Patent Portfolio: 33 issued patents; 7 pending\nOlvi-Vec covered by Composition of Matter (2031) and Manufacturing (2038)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:44.965+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7edef8d8-e404-4a67-b2f2-a2b8f87a8240", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.35, "x": 0.16, "y": 0.69 }, "kind": "list", "text": "Long Duration of Regulatory / Marketing Exclusivity", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:44.965+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cc45ef6f-22ac-453b-b188-a7385aca4d2a", "parentComponentId": null }, { "bbox": { "h": 0.07, "w": 0.78, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "Intellectual Property: Market Exclusivity & Freedom to Operate", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:44.965+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2dccdc59-2e50-47e9-a71e-99aa9676ee12", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 38, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 10, "name": "Solution (Provide relief)", "beatId": "523d1cf4-1cd0-4572-8561-e435ff7a2275", "matchId": "c6868580-ab1d-4db0-aaa6-d004c6bcc7ce", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 10-38 present Olvi-Vec as a solution, detailing its competitive advantages, clinical results, and market potential.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 29, "type": "setup", "title": "The slide uses a grid layout to categorize team members into three distinct groups: Executive Team, Board of Directors, and Operations & R&D.", "function": "other", "rawType": "team_bio", "block": null, "metadata": { "slideType": "team_bio", "slideTypeCanon": { "name": "Team bio", "slug": "team_bio", "status": "active", "canonId": "019de52d-0a7d-7394-ae5b-037478e71f1e", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "balanced", "densityScore": 49, "componentCount": 7, "textChars": 187, "nDataPoints": 0, "notes": "The slide uses a grid layout to categorize team members into three distinct groups: Executive Team, Board of Directors, and Operations & R&D.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:28:46.04+00", "seconds": 6.952, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/29", "deck": "/decks/019de075-f745-744d-a2c3-62fcecd316e9", "deckAnchor": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-29", "deckJson": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.9, "x": 0.04, "y": 0.65 }, "kind": "image", "text": "Operations & R&D headshots", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:46.04+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b0bb9982-c0a1-4f8d-b6c9-674487e04fc2", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.55, "x": 0.04, "y": 0.2 }, "kind": "image", "text": "Executive Team headshots", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:46.04+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b153ac4d-381e-4d82-b0a2-6e106fb283d6", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.3, "x": 0.65, "y": 0.15 }, "kind": "list", "text": "Board of Directors list with names, titles, and company logos", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:46.04+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4eaf36e3-d7e0-4579-b62c-1cbe7594262b", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.15, "x": 0.03, "y": 0.13 }, "kind": "paragraph", "text": "Executive Team", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:46.04+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "099f00a4-a98b-4520-a2a0-fdfdb589dfd9", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.15, "x": 0.03, "y": 0.58 }, "kind": "paragraph", "text": "Operations & R&D", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:46.04+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b7730da6-ebc6-4b81-abdc-5401d8fc9cc5", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.2, "x": 0.72, "y": 0.1 }, "kind": "paragraph", "text": "Board of Directors", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:46.04+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c10f0a99-389c-41bb-9cbc-8bbdeb7710ff", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.4, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "Accomplished Leadership Team", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:46.04+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d4f04a75-e1d1-42ba-a6dd-1cbbf87883a0", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Audience Definition", "slug": "audience-definition", "status": "active", "bestFor": null, "canonId": "019dd956-7f2a-775d-aeee-ff099bcb7756", "version": 1, "bodyDocId": null, "description": "Six key questions: Who are they? What do they know? What do they believe? What do they care about? What do they fear? What decisions can they make?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "f6bfbee0-99a7-403c-83a0-3eb3f0a8a339", "evidence": "Board of Directors list with names, titles, and company logos", "pageRefs": null, "priority": "Core", "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:33:26.294819+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 29, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 38, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 10, "name": "Solution (Provide relief)", "beatId": "523d1cf4-1cd0-4572-8561-e435ff7a2275", "matchId": "c6868580-ab1d-4db0-aaa6-d004c6bcc7ce", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 10-38 present Olvi-Vec as a solution, detailing its competitive advantages, clinical results, and market potential.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 30, "type": "resolution", "title": "The slide uses a combination of a checklist for past achievements and a timeline arrow for future goals.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "balanced", "densityScore": 44, "componentCount": 3, "textChars": 603, "nDataPoints": 1, "notes": "The slide uses a combination of a checklist for past achievements and a timeline arrow for future goals.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:28:41.485+00", "seconds": 2.257, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/30", "deck": "/decks/019de075-f745-744d-a2c3-62fcecd316e9", "deckAnchor": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-30", "deckJson": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.6, "x": 0.34, "y": 0.16 }, "kind": "diagram", "text": "Initiate Phase 2 trial in (Adjuvant Maintenance) NSCLC; Enter additional regional development & commercial partnership(s) and platform collaborations; Initiate Phase 1/2 trial in recurrent ovarian cancer (IV route); Initiate Ph1b/2 trial of V2ACT", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Timeline", "slug": "timeline", "status": "active", "canonId": "019de52d-03c5-73fc-84aa-4180cbf0f5cf", "version": 1, "description": null }, "framework": null }, "subkind": "timeline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.485+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a183f170-a29b-43d3-93d1-d55c80b4d5dd", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.28, "x": 0.03, "y": 0.21 }, "kind": "list", "text": "Executed on go public strategy and follow on with $60M raised; Initiation of Phase 3 Trial in PRROC; Phase 2 results published in JAMA Oncology; Collaboration and License agreement with Newsoara; Initiation of Phase 1b/2 trial in recurrent SCLC (China); Issuance of V2ACT US Patent", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.485+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "52cd0073-b72d-44cd-a72f-009237f48276", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.94, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "Genelux Has Executed on Multiple Milestones and is Positioned for the Future", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:41.485+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d43267ac-f578-4b2f-917f-67102ee88037", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "4af8119b-a652-441d-a54a-8a8a0b85849f", "evidence": "The slide uses a visual arrow to represent future milestones over time.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:28:41.485+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 30, "frameworkName": "timeline" } ], "arcBeats": [ { "to": 38, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 10, "name": "Solution (Provide relief)", "beatId": "523d1cf4-1cd0-4572-8561-e435ff7a2275", "matchId": "c6868580-ab1d-4db0-aaa6-d004c6bcc7ce", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 10-38 present Olvi-Vec as a solution, detailing its competitive advantages, clinical results, and market potential.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 31, "type": "analysis", "title": "Includes footnotes regarding market close date and specific financing obligations.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 57, "componentCount": 5, "textChars": 428, "nDataPoints": 11, "notes": "Includes footnotes regarding market close date and specific financing obligations.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:28:42.004+00", "seconds": 2.692, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/31", "deck": "/decks/019de075-f745-744d-a2c3-62fcecd316e9", "deckAnchor": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-31", "deckJson": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json" }, "components": [ { "bbox": { "h": 0.22, "w": 0.28, "x": 0.59, "y": 0.56 }, "kind": "callout", "text": "2023 Financing Events: January IPO ($15M), May Private Placement ($33M), June Private Placement ($18M).", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:42.004+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dc18171e-a953-408e-a571-77c8b306e4e6", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.25, "x": 0.58, "y": 0.22 }, "kind": "list", "text": "Analyst Coverage list including Bruce Jackson, Kemp Dolliver, and Jason McCarthy.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:42.004+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "72aba064-be1e-4cc4-a1d1-237f3a02138f", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.75, "x": 0.11, "y": 0.81 }, "kind": "source-note", "text": "Footnotes regarding market close date and financing reconciliation.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:42.004+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "85becfa6-4ede-4c0e-8bf6-dd9e12de4f86", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.43, "x": 0.11, "y": 0.22 }, "kind": "table", "text": "Capitalization Summary table with Stock Symbol, Share Price, Shares Outstanding, Market Cap, Cash, PIPE Commitments, and Insider Ownership.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:42.004+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cf47b978-218a-4980-b9b6-21acd70c323d", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.45, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "Expected Operating Runway into 1Q 2026", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:42.004+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "20b28002-5c43-4f7e-9b3f-9fdba9ebfc98", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 38, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 10, "name": "Solution (Provide relief)", "beatId": "523d1cf4-1cd0-4572-8561-e435ff7a2275", "matchId": "c6868580-ab1d-4db0-aaa6-d004c6bcc7ce", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 10-38 present Olvi-Vec as a solution, detailing its competitive advantages, clinical results, and market potential.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 32, "type": "resolution", "function": "summarize", "rawType": "key_takeaways", "block": null, "metadata": { "slideType": "key_takeaways", "slideTypeCanon": { "name": "Key takeaways", "slug": "key_takeaways", "status": "active", "canonId": "019de52d-06e7-7674-a891-9f7de3b11b6d", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 78, "componentCount": 7, "textChars": 755, "nDataPoints": 2, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:28:42.338+00", "seconds": 2.901, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/32", "deck": "/decks/019de075-f745-744d-a2c3-62fcecd316e9", "deckAnchor": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-32", "deckJson": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json" }, "components": [ { "bbox": { "h": 0.72, "w": 0.09, "x": 0.04, "y": 0.17 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Icon grid", "slug": "icon-grid", "status": "active", "canonId": "019de52c-fdfe-749d-9990-1db465a3eed4", "version": 1, "description": null }, "framework": null }, "subkind": "icon-grid", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:42.338+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "690d4d5a-1f4c-4768-8921-e77218074fb4", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.6, "x": 0.14, "y": 0.78 }, "kind": "list", "text": "Estimated Billion Dollar Plus Annual Market Opportunity in the U.S. Potential beyond this in numerous clinical settings", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:42.338+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1b5f0d6e-3983-423b-bc50-5033f648afa6", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.8, "x": 0.14, "y": 0.18 }, "kind": "list", "text": "Olvi-Vec: De-risked late-stage Clinical Program. Ongoing pivotal trial in late-stage Ovarian Cancer, SCLC and planned Phase 2 trial Adjuvant Maintenance NSCLC", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:42.338+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "33b3523a-4d2c-48be-8d1f-e50b91f49222", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.8, "x": 0.14, "y": 0.48 }, "kind": "list", "text": "Validating Strategic Partnerships. Newsoara Biopharma (Greater China rights) initiated a Phase 1b/2 clinical trial with Olvi-Vec in small-cell lung cancer and ELIAS Animal Health (global rights) is preparing a canine efficacy study with V-VET1", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:42.338+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a2e3d6df-5869-4268-8127-59586d6a393f", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.6, "x": 0.14, "y": 0.65 }, "kind": "list", "text": "Focused Commercial Strategy. US launch in Ovarian Cancer initially; strategic partnerships for ex-US rights", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:42.338+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d9bda4fb-8438-4d9a-ac7b-a3416a3aa836", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.6, "x": 0.14, "y": 0.33 }, "kind": "list", "text": "CHOICE™ Platform; Broad and Diverse Discovery Engine. Library with over 500 novel vaccinia strains and 110+ transgenes", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:42.338+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fecf0f0a-09ec-4cd5-8ba5-b8038de832b5", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.15, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "Highlights", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:42.338+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7bdbbae0-01e3-46b9-985e-58c7d47d39ec", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 38, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 10, "name": "Solution (Provide relief)", "beatId": "523d1cf4-1cd0-4572-8561-e435ff7a2275", "matchId": "c6868580-ab1d-4db0-aaa6-d004c6bcc7ce", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 10-38 present Olvi-Vec as a solution, detailing its competitive advantages, clinical results, and market potential.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 33, "type": "appendix", "title": "The slide indicates this is an appendix section of an October 2023 corporate presentation.", "function": "appendix", "rawType": "appendix", "block": null, "metadata": { "slideType": "appendix", "slideTypeCanon": { "name": "Appendix", "slug": "appendix", "status": "active", "canonId": "019de52d-0762-71f8-b564-89ab863301cc", "version": 1, "description": null }, "function": "appendix", "functionCanon": { "name": "Appendix", "slug": "appendix", "status": "active", "canonId": "019de52d-138d-750b-83c3-49b4bc7a7a38", "version": 1, "description": null }, "density": "sparse", "densityScore": 12, "componentCount": 3, "textChars": 79, "nDataPoints": 0, "notes": "The slide indicates this is an appendix section of an October 2023 corporate presentation.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:28:42.158+00", "seconds": 2.411, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/33", "deck": "/decks/019de075-f745-744d-a2c3-62fcecd316e9", "deckAnchor": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-33", "deckJson": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json" }, "components": [ { "bbox": { "h": 0.05, "w": 0.285, "x": 0.182, "y": 0.635 }, "kind": "paragraph", "text": "Corporate Presentation | October 2023\nAppendix", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:42.158+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "78839054-ddd1-46e5-91b6-49bc255c5cd7", "parentComponentId": null }, { "bbox": { "h": 0.025, "w": 0.325, "x": 0.162, "y": 0.578 }, "kind": "paragraph", "text": "Redefining Immuno-Oncology", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:42.158+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fa24ad24-a02a-4ed2-9ca9-033e068add69", "parentComponentId": null }, { "bbox": { "h": 0.085, "w": 0.445, "x": 0.175, "y": 0.445 }, "kind": "title", "text": "GENELUX", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:42.158+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7fcd5d5f-791f-4966-b676-d1d4b89dde9f", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 38, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 10, "name": "Solution (Provide relief)", "beatId": "523d1cf4-1cd0-4572-8561-e435ff7a2275", "matchId": "c6868580-ab1d-4db0-aaa6-d004c6bcc7ce", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 10-38 present Olvi-Vec as a solution, detailing its competitive advantages, clinical results, and market potential.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 34, "type": "setup", "title": "The slide lists key advisors, some of whom also hold executive roles (CEO, CMO, CFO) within the company.", "function": "other", "rawType": "team_bio", "block": null, "metadata": { "slideType": "team_bio", "slideTypeCanon": { "name": "Team bio", "slug": "team_bio", "status": "active", "canonId": "019de52d-0a7d-7394-ae5b-037478e71f1e", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "sparse", "densityScore": 20, "componentCount": 3, "textChars": 205, "nDataPoints": 0, "notes": "The slide lists key advisors, some of whom also hold executive roles (CEO, CMO, CFO) within the company.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:28:42.338+00", "seconds": 2.502, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/34", "deck": "/decks/019de075-f745-744d-a2c3-62fcecd316e9", "deckAnchor": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-34", "deckJson": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json" }, "components": [ { "bbox": { "h": 0.78, "w": 0.07, "x": 0.07, "y": 0.13 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:42.338+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "36561b87-6cbc-4db9-b4ee-d4b8cd2e2b19", "parentComponentId": null }, { "bbox": { "h": 0.78, "w": 0.82, "x": 0.15, "y": 0.13 }, "kind": "list", "text": "Robert Holloway, MD, Chairman; Robert Coleman, MD, Member; Albert A. Mendivil, MD, Member; Thomas J. Herzog, MD, CEO; David M. O'Malley, MD, CMO; Alan Forsythe, PhD, CFO", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:42.338+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "64141b66-9270-41d7-8f29-adfb188f6e70", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.45, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "Accomplished Clinical Advisory Board", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:42.338+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f80a7b12-c497-4ab3-b435-c5ff406b8129", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 38, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 10, "name": "Solution (Provide relief)", "beatId": "523d1cf4-1cd0-4572-8561-e435ff7a2275", "matchId": "c6868580-ab1d-4db0-aaa6-d004c6bcc7ce", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 10-38 present Olvi-Vec as a solution, detailing its competitive advantages, clinical results, and market potential.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 35, "type": "resolution", "title": "Includes microscopic imagery of patient samples (Pt.#15A-01 and Pt.#15A-11) showing longitudinal progression of treatment.", "function": "show_traction", "rawType": "key_takeaways", "block": null, "metadata": { "slideType": "key_takeaways", "slideTypeCanon": { "name": "Key takeaways", "slug": "key_takeaways", "status": "active", "canonId": "019de52d-06e7-7674-a891-9f7de3b11b6d", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "balanced", "densityScore": 43, "componentCount": 4, "textChars": 502, "nDataPoints": 0, "notes": "Includes microscopic imagery of patient samples (Pt.#15A-01 and Pt.#15A-11) showing longitudinal progression of treatment.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:28:43.132+00", "seconds": 3.198, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/35", "deck": "/decks/019de075-f745-744d-a2c3-62fcecd316e9", "deckAnchor": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-35", "deckJson": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.35, "x": 0.33, "y": 0.22 }, "kind": "image", "text": "Microscopic images showing tumor cell reduction over time (baseline, day 5, day 10) and immune activation chart.", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:43.132+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0f192e38-1675-4ead-8872-8cac73b4c151", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.25, "x": 0.72, "y": 0.22 }, "kind": "image", "text": "Microscopic images showing lymphocyte infiltration and tumor cell elimination in peritoneal and pleural fluid.", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:43.132+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ae6bed9e-f9a6-45e4-b37b-d4a6b745de5c", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.25, "x": 0.05, "y": 0.3 }, "kind": "list", "text": "Olvi-Vec treatment was able to dramatically decrease or eliminate tumor cells in multiple patient samples. The Activation of Immunosurveillance by Olvi-Vec after 2 doses was seen in multiple cavities as monotherapy.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:43.132+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8b21e0f1-fbfd-4d9a-912c-987002320017", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.94, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "Olvi-Vec Demonstrates Monotherapy Oncolysis and Immune Activation", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:43.132+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1b3382f9-c79f-42f3-9d13-189754e0f323", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 38, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 10, "name": "Solution (Provide relief)", "beatId": "523d1cf4-1cd0-4572-8561-e435ff7a2275", "matchId": "c6868580-ab1d-4db0-aaa6-d004c6bcc7ce", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 10-38 present Olvi-Vec as a solution, detailing its competitive advantages, clinical results, and market potential.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 36, "type": "evidence", "title": "The slide compares pre- and post-treatment biopsies for three patients (15A-16, 15A-18, 15A-23) using both visual microscopy and quantitative infiltration histo", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 62, "componentCount": 6, "textChars": 363, "nDataPoints": 12, "notes": "The slide compares pre- and post-treatment biopsies for three patients (15A-16, 15A-18, 15A-23) using both visual microscopy and quantitative infiltration histograms.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:28:42.862+00", "seconds": 2.816, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/36", "deck": "/decks/019de075-f745-744d-a2c3-62fcecd316e9", "deckAnchor": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-36", "deckJson": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json" }, "components": [ { "bbox": { "h": 0.16, "w": 0.16, "x": 0.02, "y": 0.6 }, "kind": "callout", "text": "Shift of CD8+ cells into epithelial tissue", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:42.862+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "35d01c21-156c-4c69-bf2a-0ddbb8734b27", "parentComponentId": null }, { "bbox": { "h": 0.16, "w": 0.16, "x": 0.02, "y": 0.2 }, "kind": "callout", "text": "Induced Infiltration of CD8+ cells into Tumors", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:42.862+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c5315bd1-1efe-413f-b50c-45236fb2ee5d", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.73, "x": 0.255, "y": 0.58 }, "kind": "chart", "text": "HALO Infiltration Histograms showing CD8+ density shifts", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:42.862+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "354a0f41-0db6-4190-9f65-59b38c57215b", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.73, "x": 0.255, "y": 0.125 }, "kind": "image", "text": "Immunofluorescence images of CD4 and CD8 cells pre- and post-treatment", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:42.862+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e8f80cdd-faea-4851-bc5b-14727ee23dfb", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.18, "x": 0.01, "y": 0.49 }, "kind": "paragraph", "text": "Endogenous TILs (intra-tumoral and stromal) are very low in ovarian cancer", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:42.862+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "86046752-1ce0-4128-856c-c33a05c3f670", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.94, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "CD8+ T-cells: Infiltrating Lymphocytes are Prognostic for Response/Survival", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:42.862+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0420b8ed-b0e2-4c4c-8c66-1507c2969ae9", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 38, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 10, "name": "Solution (Provide relief)", "beatId": "523d1cf4-1cd0-4572-8561-e435ff7a2275", "matchId": "c6868580-ab1d-4db0-aaa6-d004c6bcc7ce", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 10-38 present Olvi-Vec as a solution, detailing its competitive advantages, clinical results, and market potential.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 37, "type": "evidence", "title": "The slide uses a combination of a bar chart (ELISPOT data) and a line chart (SLD over time) to show clinical efficacy.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 59, "componentCount": 5, "textChars": 523, "nDataPoints": 4, "notes": "The slide uses a combination of a bar chart (ELISPOT data) and a line chart (SLD over time) to show clinical efficacy.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:28:43.542+00", "seconds": 3.399, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/37", "deck": "/decks/019de075-f745-744d-a2c3-62fcecd316e9", "deckAnchor": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-37", "deckJson": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json" }, "components": [ { "bbox": { "h": 0.45, "w": 0.37, "x": 0.61, "y": 0.0011 }, "kind": "chart", "text": "IFN-gamma secreting cells / 100,000 PBMCs at Baseline, Week 6, and Week 30", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Grouped bar chart", "slug": "bar-grouped", "status": "active", "canonId": "019de52c-ff3b-751e-a8ff-f21ff11097b1", "version": 1, "description": null }, "framework": null }, "subkind": "bar-grouped", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:43.542+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ebc07c22-9a15-47a4-91f7-b547d802572d", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.46, "x": 0.52, "y": 0.0052 }, "kind": "chart", "text": "SLD of target lesions over time", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:43.542+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5167ecd6-70b3-4d9c-b722-d7a027fae5a6", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.17, "x": 0.35, "y": 0.0052 }, "kind": "diagram", "text": "Treatment timeline: Last Chemo -> PD -> GL-ONC1 Tx -> Partial Response -> Stable Disease", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:43.542+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d4014358-c6a3-41f5-a219-e446135458a3", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.28, "x": 0.04, "y": 0.0018 }, "kind": "list", "text": "Key Takeaways: Off-the-Shelf Personalized Medicine: Single Agent generates Individualized Results. Olvi-Vec induces favorable & long-lasting Tumor-specific T-cell Response (TSTcR)... Documented OR from Olvi-Vec treatment after failure of last chemotherapy", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:43.542+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "895c5408-0c21-4b16-9392-d74c108f6e73", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.95, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "Long-lasting, Tumor-specific T cell response corresponds to tumor reduction", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:43.542+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ad3a2424-6206-4970-9f7f-f79991df3ae8", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "2207dd0e-5cec-4eaf-8d32-296359c83797", "evidence": "The slide contrasts the patient's state before and after Olvi-Vec treatment.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:28:43.542+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 37, "frameworkName": "before-after-bridge" } ], "arcBeats": [ { "to": 38, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 10, "name": "Solution (Provide relief)", "beatId": "523d1cf4-1cd0-4572-8561-e435ff7a2275", "matchId": "c6868580-ab1d-4db0-aaa6-d004c6bcc7ce", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 10-38 present Olvi-Vec as a solution, detailing its competitive advantages, clinical results, and market potential.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 38, "type": "resolution", "title": "The slide uses clinical study data (VIRO-15, NCT01443260) to support its claims.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 64, "componentCount": 7, "textChars": 294, "nDataPoints": 10, "notes": "The slide uses clinical study data (VIRO-15, NCT01443260) to support its claims.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:28:43.681+00", "seconds": 3.442, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/38", "deck": "/decks/019de075-f745-744d-a2c3-62fcecd316e9", "deckAnchor": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-38", "deckJson": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json" }, "components": [ { "bbox": { "h": 0.07, "w": 0.65, "x": 0.02, "y": 0.155 }, "kind": "callout", "text": "Converts Tumor Microenvironment to Inflammatory \"Hot Spot\"", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:43.681+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "04c6299d-1fbb-49d7-9501-56050ccdea02", "parentComponentId": null }, { "bbox": { "h": 0.07, "w": 0.65, "x": 0.02, "y": 0.53 }, "kind": "callout", "text": "Up Regulates Immunomodulatory Target Proteins, such as PD-L1", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:43.681+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dc09959a-e9ab-4b3d-a777-c57aeea16ce9", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.18, "x": 0.41, "y": 0.61 }, "kind": "chart", "text": "PD-L1 expression levels", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Stacked bar chart", "slug": "bar-stacked", "status": "active", "canonId": "019de52c-feec-74bf-9028-15b74f84f0a7", "version": 1, "description": null }, "framework": null }, "subkind": "bar-stacked", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:43.681+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "23c9191d-3f7a-4d46-9015-333726410a67", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.2, "x": 0.4, "y": 0.23 }, "kind": "chart", "text": "Fold-change from Baseline of cytokines", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:43.681+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7fce7c11-8794-4761-b6d7-a9c9b5c1d47e", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.32, "x": 0.66, "y": 0.63 }, "kind": "image", "text": "PD-L1 staining comparison", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:43.681+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "58af787a-6cc2-40df-a818-06d0054a44e0", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.3, "x": 0.67, "y": 0.21 }, "kind": "image", "text": "PET/CT scans showing inflammatory response", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:43.681+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5d963540-9d4c-4af9-9526-26443e74ff4f", "parentComponentId": null }, { "bbox": { "h": 0.07, "w": 0.65, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "Olvi-Vec: Ideal Backbone for Combination Therapy", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:28:43.681+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "03599159-1695-47ea-8384-b0f7705b6cc1", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 38, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 10, "name": "Solution (Provide relief)", "beatId": "523d1cf4-1cd0-4572-8561-e435ff7a2275", "matchId": "c6868580-ab1d-4db0-aaa6-d004c6bcc7ce", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 10-38 present Olvi-Vec as a solution, detailing its competitive advantages, clinical results, and market potential.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true } ], "arcBeats": [ { "from": 1, "to": 3, "label": "Problem (Identify pain)", "description": "The initial slides introduce the problem and highlight the limitations of current oncolytic immunotherapies." }, { "from": 4, "to": 9, "label": "Agitate (Make it worse)", "description": "Slides 4-9 emphasize the complications and challenges of current treatments, including resistance and refractoriness." }, { "from": 10, "to": 38, "label": "Solution (Provide relief)", "description": "Slides 10-38 present Olvi-Vec as a solution, detailing its competitive advantages, clinical results, and market potential." } ], "loops": [ { "from": 4, "to": 9, "label": "Cost Of Inaction", "description": "What if we don't adopt a new approach to oncolytic immunotherapy?" }, { "from": 24, "to": 26, "label": "Jobs To Be Done", "description": "How can Olvi-Vec address the needs of patients and healthcare systems?" } ] }